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Primary sensory afferent outgrowth within the developing longitudinal pathway 
of the spinal cord is important for intrasegmental and intersegmental communication 
that underlies coordination and development of reflexes and contributes to sensory 
perception. The endogenous mechanisms that regulate primary sensory afferent 
extension are the primary focus of this dissertation.  
This dissertation tested the hypothesis that primary sensory afferent extension in 
the longitudinal pathway is regulated by sphingosine 1-phosphate type 1 receptor 
(S1P1R) and tyrosine kinase receptor B (TrkB) through a brain derived neurotrophic 
factor (BDNF) related mechanism. To test this hypothesis we used embryonic day five 
(E5) chicken embryos, as this is the developmental time point when sensory afferents 
are growing along the longitudinal axis of the spinal cord but have not yet turned 
ventrally to make connections with the grey matter of the spinal cord. Chicken embryos 
were removed from their in ovo environment to allow for labeling of primary afferent 
neurons in the thoracic 3/4 (T3/4) dorsal root ganglia (DRG). Tissue was then put into 
culture with or without various pharmacological agents and subsequently assayed for 
length of growth of the labeled primary afferent axons along the longitudinal axis of the 
spinal cord.  
Results showed both BDNF and fingolimod-p, an S1P1R agonist known to 
increase BDNF mRNA and protein production/secretion in cortical neurons, increased 
primary axon extension along the longitudinal pathway. Further, fingolimod-p 
increased BDNF mRNA production in DRG in this system. Conversely, inhibition of 
BDNF or S1PRs attenuated primary afferent axon extension along the longitudinal 
pathway. We found BDNF signaling to be required for fingolimod-p’s effects as 
addition of αBDNF attenuated the effects of fingolimod-p on axon outgrowth.  
TrkB, the high affinity receptor for BDNF, is expressed in chicken DRG during 
embryonic development. We hypothesized that TrkB activation by BDNF regulates 
DRG axon extension in the longitudinal pathway through the PLC-γ signaling pathway. 
We found inhibition of TrkB and/or PLC-γ signaling pathway attenuated DRG axon 
extension with or without BDNF stimulation. Additional pathways associated with 
TrkB activation: mitogen activated kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K) appeared to either have no effect on DRG axon extension or were involved in 
DRG axon extension through a mechanism that is not related to TrkB.  
Collectively, these studies suggest an endogenous mechanism for the regulation 
of DRG axon outgrowth within the longitudinal pathway. With this mechanism, DRG 
axon outgrowth may be enhanced or attenuated following manipulation of S1P1R, 
BDNF and/or TrkB. Further, these findings suggest an action through BDNF on CNS 
axons as a potential therapeutic effect of fingolimod-p, a treatment for relapsing 
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Our ability to form spinal reflexes is the result of an elaborate neuronal growth 
pattern that begins in early development and requires formation of neuronal connections 
between the peripheral nervous system (PNS) and multiple segments of the spinal cord. 
The developmental events leading up to the formation of these connections are the result 
of endogenous regulation and response to exogenous cues. Sensory axons must enter the 
cord, extend the appropriate length along the cord and innervate appropriate neurons 
within the cord. Understanding the endogenous mechanisms that control important 
developmental events such as axon extension, is important for our understanding of 
reflex formation. The following body of work sought to understand the endogenous 
regulation of primary sensory afferent extension in the developing longitudinal pathway 
of the embryonic chicken spinal cord.   
THE CHICKEN EMBRYO   
 
The chicken (Gallus gallus domesticus) embryo is an advantageous model for 
developmental studies as it has a well characterized anatomical development. 
Descriptions of chicken embryo development were published in 1951 when Victor 
Hamburger and Howard Hamilton published a paper entitled: “A series of normal stages 
in the development of the chicken embryo” (Hamburger and Hamilton, 1951). This 
document contained a comprehensive depiction of normal chicken development from the 
earliest HH st.1, prior to the formation of the primitive streak, until hatching at HH st.46. 
Hamburger and Hamilton’s document was the first of its kind to provide illustrations and 
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written descriptions for all stages of chicken  embryo development, allowing for more 
accurate identification of embryonic age (Hamburger and Hamilton, 1951).  
The chicken embryo has many advantages over mammalian models, with the 
most obvious advantage being that development occurs outside of a live animal. This 
system allows for greater access to the developing embryo, making surgical manipulation 
and neuronal labeling a less difficult endeavor than in mammalian embryos. In regards to 
the study of primary afferent growth, the chicken embryo is an advantageous model 
because the pattern in which afferents grow and establish connections with the CNS is 
well characterized (Eide and Glover, 1995, Coutinho-Budd et al., 2008). 
Scrutiny of both the anatomy and cytoarchitecture of the chicken spinal cord 
reveals close resemblance to mammalian spinal cord. Both the chicken and the mammal 
contain grey matter consisting of motor neuron cell bodies, interneurons and various glial 
cells. Further, the grey matter is stratified into ten domains, each with unique 
cytoarchitecture known as Rexed lamina. Layers I-VI occupy the dorsal horn, layers VII-
IX constitute the ventral horn and layer X surrounds the central canal of the spinal cord 
(Martin, 1979). Surrounding the grey matter is a layer of white matter containing 
ascending and descending myelinated axons that form ventral, lateral and dorsal funiculi.  
A further parallel between these models lies within the somatosensory reflex 
system. Both mammals and chicken contain a reflex system in which stimulation of a 
peripheral receptor sends afferent signals to the spinal cord. The cell bodies of these 
afferents are located in dorsal root ganglia (DRG) located adjacent to each segmental 
level of the spinal cord. Axons may enter different laminae of the spinal cord and synapse 
directly onto motor neurons or interneurons, or may ascend and descend rostrally and 
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caudally within the ipsilateral dorsal funiculus to then innervate neurons in multiple 
segments of the spinal cord (Martin, 1979, Ozaki and Snider, 1997). 
While there are many advantages to the chicken embryo model, the use of this 
model is tempered by a major disadvantage. Unlike the mouse, transgenic technologies 
have proven to be extremely difficult in the chicken. This is in part due to the 
reproductive system of the laying hen. The first 20-24 hours of embryonic development 
begins in the hen oviduct where a significant amount of cell division and growth occurs. 
By the time the egg is laid, the embryo consists of >60,000 undifferentiated cells. During 
this time, the embryo is inaccessible to manipulation making the use of many genetic 
techniques technically difficult (Menna et al., 2003). As a result, techniques using 
retroviral vectors and morpholinos to introduce exogenous genes have been developed 
(Michael et al., 1997). While these methods for exogenous gene expression have allowed 
for genetic manipulation within the chicken embryo model, there are limitations that 
makes using these methods difficult in early developmental studies. Both retroviral 
vectors and morpholinos have been used effectively to knockdown and/or knock in 
specific genes into the chicken embryo. However, use of these techniques require 
injection or electroporation of retrovirus at early stages of development which may alter 
the development of afferents prior to the time point in which afferents begin to extend 
within the longitudinal pathway (Krull, 2004). Electroporation at early stages of 
development can be problematic as injection of current puts stress on the developing 
embryo which could result in damage to the developing afferents and alteration of 
growth.    
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 The chicken embryo is the most appropriate model system for this work 
for the following reasons. First, all experiments conducted in this work were done at an 
early developmental stage that is easily accessible in a chicken model, yet more difficult 
to access in a mammalian embryo. Second, we were interested in the developmental 
growth of DRG axons in the longitudinal pathway, an anatomical pathway that is easily 
labeled in situ in chicken. Thus, the following investigation makes use of the chicken 
embryo at embryonic day (E5), HH st.25. This is an ideal time to investigate longitudinal 
afferent extension within the longitudinal pathway because afferents have entered into the 
spinal cord, bifurcated and have begun to extend rostrally and caudally along the 
longitudinal axis of the spinal cord. At this time, afferents have not invested into the grey 
matter of the spinal cord and will not do so until E8. 
Experimental preparation: advantages and disadvantages  
The experimental preparation utilized in this work requires that an embryo be 
removed from its in ovo environment. Following injection of tracing materials and 
pharmacological manipulation, the embryo is placed into a culture dish containing a 
sterile cell culture insert known as a Millicell [Figure 1-1A,B]. The preparation is then 
placed into an incubator at 37°C for 5 hours. One important advantage of this preparation 
is that it allows for controlled drug delivery to the embryo. The in ovo environment 
contains many layers of material with various solubility characteristics, making the 
concentration of drug delivery to the embryo impossible to calculate (Menna et al., 2003). 
Isolation of the embryo from the in ovo environment and drug treatment in culture allows 
a more precise drug delivery to the embryonic tissues.   
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Additionally, maintenance of the substrate upon which these axons grow is 
essential, as the molecular composition of this substrate has yet to be characterized. 
Investigations using dissociated DRG neurons to study axon growth rates utilize different 
substrates. As a result, different growth rates and responses to pharmacological agents 
have been observed (Ketschek et al., 2007, Koch et al., 2012). Thus, it is essential that the 
endogenous substrate be maintained in order to accurately investigate endogenous 
regulation of growth. 
Additionally, this preparation allows ease in injecting tracing materials into the 
DRG and maintenance of the integrity of the afferents and the substrate upon which DRG 
axons grow. Previous labeling experiments using DiI, a lipophilic cell tracing material 
demonstrate that neither dissection nor DiI injection damages the central or peripheral 
projecting afferent of the DRG [Figure 1-1C]. Maintenance of both the central and the 
peripheral projection is essential for normal growth, as it has been shown that damage to 
the peripheral projection enhances growth of the central projection (Yang and Yang, 
2012). It is important that DRG axons are not damaged, as the preparation is designed to 
analyze growth of intact axons and not regenerating axons.  
 
DORSAL ROOT GANGLIA AND DORSAL ROOT ENTRY ZONE ANATOMY 
AND DEVELOPMENT  
 
DRG origin and development 
 
Dorsal root ganglia are a heterogeneous population of neural crest derived cells. 
Their primary function is to provide somatosensation, nociception and proprioception to 
the entire body with the exception of the face.  
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Dorsal root ganglia development begins with neural tube closure and dorsal 
migration of neural crest cells (NCC) at every level of the spinal cord. In the chicken 
embryo, migration of  NCCs destined to become DRG begins at embryonic day 2 (E2), 
Hamburger Hamilton stage 12 (HH st.12) and is complete by E3 (HH st.20) (Lallier and 
Bronner-Fraser, 1988, Rifkin et al., 2000). Chicken DRG neurogeneis occurs between E3 
and E6. Experiments using [3H] thymidine labeling to label dividing cells in ovo found 
[3H] thymidine labeled DRG neurons at E3-5, with unlabeled neurons appearing at E4 
and no label after E6. These data suggest neurons had withdrawn from the cell cycle by 
E6 and that DRG neurons originate between E3 and E6 (Scott, 1990). 
Once DRG position is established, neurons extend peripheral and central afferents 
in a highly characterized manner. At E3 (HH st.19), DRG neurons extend afferents 
centrally toward the developing spinal cord and peripherally toward the developing 
muscles and skin (Eide and Glover, 1995). Sensory afferents enter the spinal cord via a 
region known as the dorsal root entry zone (DREZ) at each segmental level of the spinal 
cord [Figure 1-2A] (Sprague, 1958).  
The DREZ is a unique anatomical region where primary sensory afferents from 
each segmental level enter into the spinal cord. Afferents extend central projections 
towards the DREZ and not to other areas of the spinal cord or notochord due to chemo-
repulsive cues from these regions (Masuda et al., 2009). Demarcating the developing 
DREZ is a unique population of multipotent stem cells called boundary cap cells. These 
cells are located at axon entry and exit points in the spinal cord. Their primary function is 
thought to be regulation of sensory axon bundle ingrowth into the spinal cord (Hjerling-
Leffler et al., 2005). In the mature animal, the DREZ is surrounded by a thickened layer 
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of glia called the glia limitans. These structures form barriers with channels for 
myelinated and non-myelinated axon bundle penetration. The only structures permitted to 
transverse this region are the axons (Fraher, 1999). 
 Prior to afferent entry into the DREZ, DRG neurons maintain a bipolar 
morphology within the ganglia. As development progresses, the two opposing processes 
fuse to form a single extension of the cell body’s cytoplasm, thus giving DRG neurons 
pseudounipolar morphology (Takahashi and Ninomiya, 1987). By E4.5, in the developing 
chicken embryo, the central process of the DRG cells have entered the DREZ and have 
branched rostrally and caudally to establish the longitudinal pathway [Figure 1-2B]. In 
the in situ preparation used in this study, chicken DRG central afferents growing within 
the longitudinal pathway at E5, HH st.25, extend axons at a rate of 56.64µm/ hr-1 
(McNamara et al., 2015; unpublished findings).   
Organization of this pathway follows a somatotopic and modality based pattern 
(Brown et al., 1974). Following longitudinal extension (E8; HH st.34), the centrally 
projecting axons simultaneously invest into each segmental level of the grey matter of the 
spinal cord to establish intrasegmental and intersegmental connections with neurons and 
interneurons within the developing spinal cord [Figure 1-2C]. This pattern of 
development underlies the coordination of reflex formation (Davis et al., 1989). 
Following grey matter investment, some afferents continue to lengthen as a single bundle 
up until E10. Following E10, longitudinal axons segregate into either the dorsal funiculus 
or Lissaurer’s tract (dorsolateral fasiculus) (Eide and Glover, 1995). Analysis of these 
axons at the electron microscopic level  shows the number of axons within the dorsal 
funiculus is highest during embryonic development and significantly diminishes 
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following birth and postnatal development due most likely to cell death (Chung and 
Coggeshall, 1987). During development, programed cell death occurs in all sensory 
ganglia. In the chicken DRG, programmed cell death occurs in 30% of neurons within the 
developmental time period of HH st. 25-38 (Hamburger and Levi-Montalcini, 1949, 
Wetts and Vaughn, 1998).  
In addition to the central projection, the peripheral projection of DRG neurons 
connect to a variety of sensory receptors in the periphery. The type of peripheral receptor 
afferents connect with is dependent upon the tyrosine kinase receptor (Trk) expressed by 
the cell body of the DRG. In adult rat DRG, TrkA expressing neurons contain little to no 
myelin, are small in diameter (<30µm), and innervate nociceptors. TrkB expressing 
neurons are myelinated, are variable in size and innervate high threshold receptors. TrkC 
expressing neurons are myelinated, large in diameter (>30µm) and innervate low 
threshold receptors (McMahon et al., 1994). The Trk profile of these cells changes 
throughout early development, however whether Trk receptor profile in the early embryo 
affects the future differentiation pattern or function is unknown (Rifkin et al., 2000).  
 
THE AXON AND AXON OUTGROWTH 
The theory that axons are a distinct, morphological component of nerve cells was 
first recognized by Wilhelm His in 1887. His observed continuity between post mitotic 
neurons and their growing axons. This observation was in direct contradiction with the 
previously held notion that the nervous system was composed of a continuous, reticulum 
of fused processes. In later studies, using a silver staining technique developed by 
Camillo Golgi, Santiago Ramon Y Cajal was able to identify the structure of the growth 
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cone in unmyelinated embryonic neurons. Using this technique, Cajal described the 
growth cone as a rounded, enlargement at the distal end of the axon containing a 
“neurofibrillary bundle” (de Castro et al., 2007). These structures would later be 
identified as actin filaments and microtubules. Upon further investigation, Cajal observed 
that axons follow what appeared to be a predefined direction. Cajal postulated that during 
migration growth cones are guided by chemical signals. These early studies set precedent 
for later analysis of the growth cone and axon growth during development (de Castro et 
al., 2007).    
Advances in immunoflourescent techniques have confirmed Cajal’s initial 
observations of the growth cone, and further identified more specific components of this 
structure. Within the growth cone are three structural domains: the peripheral (P) domain, 
transition (T) domain and central (C) domain. Within the P-domain are two, distinct 
structures: the lamellipodia and the filopodia. The lamellipodia consist of a mesh-like 
network of actin fibers whereas the filopodia consist of filamentous actin (F-actin) 
[Figure 1-3]. Time lapse microscopy reveals both of these structures are highly dynamic, 
forming, extending and retracting processes over a second to minute time courses 
(Steketee et al., 2001). 
The T-domain contains arch like actin filaments that lie perpendicular to the actin 
filaments of the P-domain. As the growth cone advances, actin within the T-domain 
functions to compress microtubules within the central domain, an important process for 
crosslinking microtubules into bundles and positioning microtubules into closer 
proximity to microtubule associated proteins (MAPS).  MAPS are proteins required for 
stabilization of microtubules and coordinated interactions between actin and 
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microtubules. Previous investigations of Tau, a developmentally regulated MAP, found 
this protein to be important for neurite outgrowth and extension. In chicken DRG, 
microCALI ablation of Tau protein in vitro resulted in reduced number and length of 
neurites as well as a decrease in neurite extension rate (Liu et al., 1999). 
The C domain of the growth cone consists of an unstable population of 
microtubules that do not associate with MAPs and thus remain de-fasciculated. These 
microtubules undergo dynamic instability, alternating between slow, positive end growth 
and rapid positive end disassembly. The result is microtubule penetration of the T and P 
domains where they interact with F-actin. This functions to produce a radial array of 
microtubules across the P domain, an important morphology for axon extension.  
Also within the C-domain of the growth cone is a stable group of microtubules, 
organized into bundles by MAPs. These microtubules are oriented with their positively 
charged, polymerizing ends towards the T-domain. The role these microtubules play in 
the growth cone is not entirely understood, although it has been suggested that they may 
incorporate into the growing axon (Prokop, 2013).  
Axon outgrowth requires the coordination of actin and microtubules. In one study 
using dissociated sympathetic neurons, the rate of growth cone advance was directly 
correlated with size and dynamics of lamellipodia and filopodia (Argiro et al., 1984). 
Another study using dissociated embryonic chicken DRG found lamellipodia and 
filopodia dynamics and extension rates were greatest at the leading edge of the growth 
cone, whereas at the base of the growth cone, filopodia had a greatest rate of retraction, 
often retracting into the axon/neurite (Bray and Chapman, 1985). These studies suggest 
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lamellipodia and filopodia formation and dynamics are important events required for 
axon/neurite extension. 
Previous investigations on the rate of sensory afferent extension report a range of 
growth rates that are highly dependent upon whether observations are made in vivo or in 
vitro. Embryonic DRG axon growth rate in chicken is dependent upon the substratum 
upon which cells are plated. For instance, DRG plated on laminin grow at a rate of 54 µm 
h-1 whereas axons grow at a rate of 36 µm h-1 when plated on polylysine  (Ketschek et al., 
2007). Previous investigations of peripheral trigeminal axon extension in E10-13 chicken 
in ovo report a growth rate of 20µm h-1 (Davies, 1987). While Coutinho-Budd et al., 
(2008) calculated the growth rate for chicken DRG afferents to be 22 µm h-1 between E4-
E6, the growth rate of E5 DRG axons in vivo or in the in situ preparation used in this 
work is yet to be characterized (Coutinho-Budd et al., 2008). 
More recent studies using video enhanced contrast differential interference 
contrast (VEC-DIC) microscopy demonstrate axon growth requires three distinct 
morphological stages. First, the axon protrudes F-actin containing filopodia and 
lamellipodia, second axon engorgement occurs when vesicles and organelles invade the 
protruding lamellipodia and third, consolidation of the axon results when F-actin 
depolymerizes in the T-domain, membrane shrinking and the formation of an axon shaft. 
The end result is axon outgrowth (Dent and Gertler, 2003) [Figure 1-4].  
Also required for axon outgrowth and extension is an increase in cell surface area. 
To accomplish this, growing neurons must undergo membrane insertion. This membrane 
is translocated from intracellular locations and inserted into the neuron cell membrane. 
One point of controversy is where in the neuron this membrane is inserted. One approach 
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to study this question is to analyze the overall movement of the neuronal cell surface 
relative to stationary objects within the cell surface (Bray, 1979). Using this approach, 
Dai and Sheetz (1995) demonstrated membrane insertion occurs at the growth cone. 
Using antibody coated beads that bind to membrane glycoproteins and lipids, Dai and 
Sheetz demonstrated that this bead moved towards the cell body at a rate five times 
greater than that of axon extension in these neurons. From these studies, Dai and Sheetz 
suggest that membrane insertion occurs at the growth cone and that a gradient of 
membrane tension, with highest tension in the cell body and lowest tension in the growth 
cone, permits membrane addition at the growth cone and retrograde flow of membrane to 
the axon (Dai and Sheetz, 1995).  
In contrast to these findings, Popov et al., (1992) suggest membrane insertion 
occurs throughout the entire neurite and cell body of the neuron. Using cultured spinal 
neurons from Xenopus, Popov et al., (1992) used fluorescent labeling techniques to 
analyze the rate of membrane flow in different areas of the neurite relative to fixed 
reference points within the neurite. The result was evidence that membrane addition 
occurs throughout the neurite and cell body, with increased membrane addition at 
locations further from the soma (Popov et al., 1993).   
 
Molecular factors controlling afferent growth and axon guidance   
 
Throughout development, afferent axon growth and guidance is regulated by 
complex molecular events that mediate attraction, repulsion and growth of axons. Within 
the in situ environment, axons encounter multiple guidance cues and respond by 
extending and/or retracting axons or directional turning. The influence of these factors 
allows for axon pathfinding within the longitudinal pathway.   
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Netrins are a family of long range diffusible molecules that through interactions 
with receptor deleted in colorectal cancer (DCC) receptor mediate chemoattractive effects 
or UNC receptors mediate chemorepulsive effects. During early development (E10-11; 
mouse), netrins are expressed in the floor plate of the ventral spinal cord of the 
developing neural tube where via interactions with UNC receptors prevent afferent 
growth towards the ventral spinal cord (Masuda et al., 2009).  
Later in development, netrins are secreted from the dorsal spinal cord. Interaction 
with the Unc5c receptor is one of the receptor ligand interactions shown to regulate 
pathfinding of DRG axons in the developmental time period following bifurcation of 
afferents but before investment into the grey matter. Wantanabe et al., (2006) found 
netrin-1 is expressed and secreted from the dorsal spinal cord in a restricted 
developmental window when afferents have yet to turn centrally into the grey matter of 
the spinal cord (E12.5; mouse).  This study found netrin-1 Unc5c interactions prevented 
DRG axon investment into the ventral spinal cord (Watanabe et al., 2006). 
After DRG axons enter into the DREZ at E3 (chicken), they must then bifurcate 
to establish the longitudinal pathway. This bifurcation is regulated by Cardiac Natriuetic 
Peptide (CNP), a member of the natriuetic peptide family. While CNP is classically 
thought to regulate homeostatic control of body water and salt, it has also been shown to 
act as a cue for control of axon branching, extension and guidance during the 
development of the longitudinal pathway (Zhao and Ma, 2009).  
Bifurcation of DRG afferents is followed by rostral and caudal extension within 
the longitudinal pathway. Recent studies of DRG axon extension in the longitudinal 
pathway point to the involvement of many different factors in the regulation of axon 
14 
 
extension within this pathway. For instance, previous investigations suggest G protein 
coupled receptors (GPCRs) are important for DRG axon growth within the longitudinal 
pathway. In these studies, pharmacological manipulation of cyclic adenosine 
monophosphate (cAMP) signaling resulted in attenuated or enhanced axon extension. 
Specifically, activation of adenylate cyclase attenuated afferent extension whereas 
inhibition of cAMP substrate, PKA enhanced afferent extension (Coutinho-Budd et al., 
2008). Additionally, inhibition of myosin II, a mechanoenzyme known to be involved in 
generating contractile forces necessary for cell motility, attenuates afferent extension in 
the developing longitudinal pathway (Robinson et al., 2015). 
There are many molecular factors known to control DRG afferent pathfinding and 
guidance including: Semaphorins, Sonic hedgehog (SHH) and neurotrophins. A summary 
of these factors and their influence on afferent pathfinding and guidance is depicted in 
Figure 1-5.  
Semaphorins are a family of long-range, diffusible, guidance factors known to 
influence DRG pathfinding in situ via their interactions with plexin A1 and A3 receptors. 
In chicken, Sema5B is expressed in the dorsal horn of the spinal cord at E5, when axons 
are extending along the longitudinal axis of the cord. Sema5B expression is attenuated by 
E8, the developmental time point when axons invest within the grey matter of the 
developing spinal cord. In vivo investigations of the role of Sema5B found knockdown of 
Sema5B using short hairpin RNA (shRNA) resulted in premature investment of DRG 
axons into the grey matter of the developing spinal cord suggesting Sema5B is an 
important factor for pathfinding for developing DRG (Liu et al., 2014). Thus, both 
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semaphorins and netrins are secreted at E5, when afferents are extending within the 
longitudinal pathway of the developing spinal cord.  
Sonic hedgehog signaling is also known to be important for DRG axon guidance 
in E13.5 rat. Through its canonical signaling pathway Patched (Ptc), SHH relieves 
inhibition of a transmembrane bound protein known as Smoothened (Smo). Activation of 
Smo leads to subsequent activation of Gli transcription factors which have been shown to 
promote turning of afferents towards SHH sources via an unknown mechanism. SHH 
also acts through a non-canonical pathway in which it activates Src family kinases 
(SFKs).  Investigations of non-canonical SHH signaling revealed inhibition of SRK 
activity in the presence of SHH prevented dissociated embryonic commissural axons 
from turning towards SHH sources (Yam et al., 2009). Thus, these findings would 
suggest SHH signaling is important for axon turning. Whether these signaling pathways 
are important for afferent extension and pathfinding within the longitudinal pathway has 
yet to be investigated.  
Neurotrophic factors are known to act as axon guidance factors for sensory axons 
as well. Previous studies show NT4 and BDNF are important factors for geniculate 
ganglion axon guidance towards fungiform papilla epithelium, the tissue that will 
differentiate into taste buds (Runge et al., 2012). Additionally, zebrafish spinal neurons 
grown on laminin were shown to turn in response to exogenous application of BDNF 
delivered to an in vitro assay via pulsatile injection from a micropipette (Chen et al., 
2013). These results suggest neurotrophins, potentially through their high affinity 






Neurotrophins are a family of structurally homologous proteins consisting of: 
nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4 (NT-4) (Chu-Wang and Oppenheim, 1978). NGF was the first 
member of this family to be identified and isolated from mouse salivary gland (Levi-
Montalcini and Hamburger, 1951, Levi-Montalcini and Angeletti, 1964). To uncover 
NGF’s function, an antiserum was developed and injected into newborn rodents. The 
result was rodents with a severely deficient to absent sympathetic nervous system and 
sensory ganglia (Levi-Montalcini and Booker, 1960). These results were the first 
evidence of a molecular factor regulating neuronal survival during development. In 
mouse, genetic knockdown of either NGF or TrkA results in a loss of 70-80% of DRG 
neurons (Farinas, 1999). 
The sequencing of NGF provided a platform for the preparation of synthetic 
oligonucleotides, complementary DNA and the cloning of human, mouse, bovine and 
chicken genes, all with a high degree of interspecies sequence homology (Scott et al., 
1983, Large et al., 1989). The remainder of the neurotrophin family (BDNF, NT3, 
NT4/5) were found to contain the ability to support growth, differentiation and survival in 
both the developing and mature nervous system (Misko et al., 1987).  
Each member of the neurotrophin family is synthesized as a pre-pro-protein. 
Removal of the N-terminal pre signal results in a pro-neurotrophin that may act on the 
low affinity P75NTR subsequently inducing P75NTR signaling (Berg et al., 1991). In 
terms of neurite outgrowth, pro-neurotrophins have been shown to activate neurite 
outgrowth through activation of RhoGTPases (Lee et al., 2001, Teng et al., 2005).  
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Processing of the pro-neurotrophin into the mature neurotrophin occurs in the 
Trans-Golgi network. Here, pro-forms of neurotrophins encounter serine proteinases 
known as convertases.  Of the convertases, Pace4, PC5/6 and furin have been shown to 
participate in the processing of neurotrophins  (Seidah et al., 1996a, Seidah et al., 1996b). 
Once neurotrophins are cleaved into their mature form they may be shuttled to the plasma 
membrane and released into the extracellular space via exocytosis (Lim et al., 2007). The 
mature forms of neurotrophins contain similar motifs and structures as well as the ability 
to form high affinity homodimers and low affinity heterodimers with NT3. (McDonald 
and Hendrickson, 1993, Narhi et al., 1993, Jungbluth et al., 1994). 
 
Brain derived neurotrophic factor (BDNF) overview 
In 1982, Barde et al. (1982) isolated  2 μg of an unknown factor from 3 kg of 
homogenized pig brain (Barde et al., 1982). In this seminal work Barde demonstrated that 
this factor, hence forth known as BDNF, could support survival, neurogenesis and neurite 
extension in cultured embryonic chicken neurons (Lindsay et al., 1985, Ockel et al., 
1996). Since its discovery, BDNF has taken the lead as the most influential and 
thoroughly characterized member of the neurotrophin family.  
 
BDNF: Roles in developing DRG 
BDNF was first appreciated for its roles in promoting survival and neurite 
outgrowth in embryonic sensory neurons in vitro. For instance, BDNF enhances neurite 
number and outgrowth in dissociated sensory neurons of the nodose ganglion and DRG 
during the embryonic period of E6-12 (Lindsay et al., 1985). Explant cultures of chicken 
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DRG and all additional sensory ganglia respond to BDNF during early development as 
well (Davies et al., 1986). In vivo, BDNF has been shown to promote target innervation 
and axon arborization (Cohen-Cory and Fraser, 1995, Huang et al., 2007). Further, mouse 
genetic knockouts for BDNF results in smaller stature, defective coordination, movement 
and balance, degeneration of sensory ganglia and death in the second postnatal week 
(Ernfors et al., 1995b, Liebl et al., 1997). Thus, these studies set the precedent for our 
investigations into the potential role of BDNF in afferent extension in the developing 
chicken embryo.   
 
BDNF: Sources and signaling 
 
 Although BDNF is known to promote survival and neurite extension in 
embryonic neurons, the location of BDNF sources within the embryo is not well 
understood. The process of finding these sources in embryonic tissue has been an arduous 
task due to the low concentration and low molecular weight of this protein (MW: 27kDa) 
(Barakat-Walter, 1996). Further, competing evidence regarding whether BDNF acts 
locally in an autocrine/paracrine manner or via long range signaling further complicates 
this issue. 
 BDNF is known to act as a target derived factor as well as in an 
autocrine/paracrine manner. Evidence that BDNF affects neurons via long range 
signaling stems from observations that sensory axons grow towards targets containing 
BDNF. Huang et al., (2007) found that trigeminal nerves in Xenopus embryos extend 
long distances towards the cement gland, a transient, embryonic structure known to secret 
BDNF (Huang et al., 2007). Additionally, previous investigations suggest BDNF is 
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released from the developing spinal cord where it can be taken up by E7-14 DRG 
neurons and retrogradely transported within the cell (Ba et al., 2010). These findings 
suggest BDNF signals to neurons from a distal source.  
In contrast, it has been suggested that BDNF signals in an autocrine/ paracrine 
manner. For instance, using E4.5 chicken sensory neurons in low density cultures, Wright 
et al., (1992) found DRG neurons synthesize their own BDNF and signal in an autocrine 
and paracrine manner  (Wright et al., 1992). Further evidence for BDNF autocrine/ 
paracrine signaling derives from BDNF’s short plasma half-life of 0.92 minutes. This 
short half-life limits the ability of BDNF to act in locations distant from the BDNF source 
(Poduslo and Curran, 1996, Robinson et al., 1996).  
Further evidence for BDNF autocrine/paracrine signaling comes from 
investigations of anterograde transport of BDNF. Anterograde transport of BDNF has 
been observed in rat DRG, optic nerve and hippocampus (Menna et al., 2003, Ng et al., 
2007). In one investigation, immunoreactivity for BDNF was observed in the axon 
terminals of adult rat DRG central and peripheral processes. Further 
immunohistochemical analysis of cervical spinal cord with attached DRG found BDNF 
protein accumulation in the dorsal horn of the spinal cord suggesting that BDNF is 
anterogradely transported within the DRG central process and released into the dorsal 
spinal cord (Michael et al., 1997). Additionally, the rate of anterograde transport for 
BDNF has been determined in E18 rat hippocampal neurons has been calculated to be 
1.49µm s-1  (Lo et al., 2011). 
   While compelling evidence exists in support of both target derived BDNF 
signaling and autocrine/paracrine signaling, it seems likely that autocrine/paracrine 
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signaling regulates afferent extension within the longitudinal pathway. This is because 
afferents are extending both rostrally and caudally within the longitudinal pathway. 
Although possible, it is unlikely that an afferent would branch to grow in opposite 
directions along a target derived BDNF gradient. 
 
FINGOLIMOD-P AND SPHINOSINE-1 PHOSPHATE RECEPTORS 
 
Fingolimod-phosphate (fingolimod-P), is a novel immune-modulator previously 
shown to increase production of BDNF mRNA and protein in embryonic neurons 
(Deogracias et al., 2012, Doi et al., 2012). Originally synthesized in 1992 through 
modification of a fungal metabolite isolated from the culture media of Isaria sinclairii, 
the effects of this compound on the CNS were largely unknown. (Fujita et al., 1994).  
Fingolimod is phosphorylated by sphingosine kinase 1/2 (Sphk1/ Sphk2) to its 
bioactive form, fingolimod-p. A linear relationship is observed between dose 
administration and blood concentrations of fingolimod and fingolimod-p (Brinkmann et 
al., 2002). Once active, fingolimod-p binds competitively to sphingosine 1-phosphate 
receptors type 1,3,4,5 (S1P1, S1P3, S1P4 and S1P5) with sub-nanomolar affinities 
(Brinkmann et al., 2002).  Once fingolimod-p is bound, the S1P receptor undergoes 
endocytosis, ubiquitination and degradation (Oo et al., 2007).  
S1PRs are a family of G-protein coupled receptors (GPCRs) found in nearly every 
tissue in the body. Within this family there are five known S1P receptor subtypes, S1P1-5 
all of which bind with high affinity to S1P, a potent, sphingolipid metabolite. A 
concentration gradient for S1P is found within the body with high S1P concentrations in 
the plasma (0.1-0.6µm) and blood (400-900nm) and lower concentrations within tissue 
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(0.5-75 pmol/mg) (Berdyshev et al., 2005). The purpose of this concentration gradient is 
thought to allow for S1P1R mediated migration of T lymphocytes from secondary 
lymphoid tissue to the circulation (Edsall and Spiegel, 1999). 
Recent analysis of the crystal structure of the S1P1 receptor has led to important 
insight into the selectivity of all S1P receptors. The S1P receptor family contains a GPCR 
morphology with seven transmembrane domains. A particularly important feature of 
these receptors is a two looped structure located on the extracellular surface. When these 
loops come together they form a cap that prevents binding of amphiphatic extracellular 
ligands. As a result, S1P is thought to bind to S1P receptors via lateral diffusion within 
the plasma membrane (Parrill et al., 2012).  
Uncovering the S1P1R crystal structure has allowed for the development of two 
classes of selective agonists. Class I agonists are lipid like and mimic S1P ligands. A 
prototypical example, fingolimod-p binds to the S1P1R causing receptor internalization, 
and degradation. The other form of S1P agonists within class I are non-lipid, small 
molecules. A classic example of these agonists is SEW2817. Computational modeling 
and mutational studies support the idea that this agonist receptor pair utilizes hydrophobic 
interactions between R residues within the S1P1R binding pocket and the negatively 
charged trifluoromethyl ring on SEW2817 to mediate the agonist response (Jo et al., 
2005).  The second class of agonist consists of small molecules that do not require 
interactions with the polar head groups of the S1P1R binding pocket but rather, require 
ionic bonds and aromatic interactions with residues within S1P1R binding pocket. The 




Sphingosine 1-phosphate (S1P)  
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in 
cell survival, cytokine production, signal transduction, cell motility/ migration and 
lymphocyte trafficking (Goetz et al., 1999, Price et al., 2008, Meng et al., 2011, Kong et 
al., 2014). Synthesis of S1P occurs via two means:  in the ER from ceramide or in the 
plasma membrane in response to stimulus induced cleavage of glycoproteins. Thus, 
levels of S1P are regulated not only by biosynthesis but by degradation pathways 
mediated by S1P phosphatases and S1P lyase (Mandala et al., 2000, Vogel et al., 2009). 
Balance between S1P synthesis and degradation is critical, as its regulation is essential 
for the operation of nearly every system in the body.  
Development is profoundly affected by the operation of S1P.  Inhibition of 
Sphk1/2 during embryonic development results in cranial neural tube deficits, vascular 
malformations and 100% lethality by E12.5 in mouse (Mizugishi et al., 2005). 
Additionally, pathfinding errors in Sphk mutants have been observed in developing axons 
(Strochlic et al., 2008).  
 
Fingolimod-p mechanism of action  
Fingolimod-p is a structural analogue of S1P and has been shown to inhibit 
lymphocyte egress from lymphoid tissue without inducing generalized 
immunosuppression. There are two theories regarding the mechanism used by 
fingolimod-p to prevent lymphocyte egress from lymphoid tissue. First, fingolimod-p has 
been shown to induce receptor internalization on lymphocytes. This effectively prevents 
signaling and function of the S1P1 receptor (Pham et al., 2008). Second, there is evidence 
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to suggest that fingolimod-p acts upon S1P1 receptors on the endothelium to close egress 
portals (Wei et al., 2005, Sanna et al., 2006). Thus, while compelling evidence exists for 
both theories, a clear mechanism of Fingolimod-p-S1P1 mediated inhibition of 
lymphocyte egress has yet to be clearly defined. 
 In theory, fingolimod-p would have been an ideal drug treatment for individuals 
who had undergone organ transplantation and were being treated with cyclosporine, a 
conventional immunosuppressive agent (Budde et al., 2002, Tedesco-Silva et al., 2005). 
However, despite early positive results, fingolimod-p was later found to induce adverse 
side effects such as bradycardia, lymphopenia/leukopenia and nephrotoxicity in healthy 
and transplant patients (Mulgaonkar et al., 2006, Schmouder et al., 2006). Further, long 
term studies demonstrated that fingolimod-p in combination with cyclosporine failed to 
decrease organ rejection rates. (Salvadori et al., 2006). As a result, clinical trials were 
terminated. 
Despite early failures in transplantation studies, fingolimod-p was found to be a 
promising disease modifying treatment (DMT) in experimental autoimmune 
encephelomyelitis (EAE), a model for multiple sclerosis (MS), a progressive 
demyelinating disease of the CNS affecting an estimated 2.5 million individuals (Fujino 
et al., 2003). Clinically, disease presentation occurs in two patterns: the more prevalent 
RRMS (80% of all cases) and less common primary progressive (PPMS) (20%). RRMS 
is characterized by phases of symptom relapse followed by full recovery or recovery with 
persistent deficit leading to a secondary progressive pattern. (Confavreux et al., 2000, 
Williams et al., 2014). Clinical trials with fingolimod-p showed treatment with 
fingolimod-p resulted in decreased gadolinium enhanced lesions on MRI analysis and 
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decreased number of symptom relapses than those treated with other DMTs (O'Connor et 
al., 2009, Comi et al., 2010, Khatri et al., 2011). Currently, fingolimod-p is considered to 
be a highly efficacious DMT for the treatment of RRMS. 
In 2007, Foster et al., (2007) demonstrated that fingolimod-p could penetrate the 
blood brain barrier, localize to the white matter and influence glial repair mechanisms, 
opening the door for investigations into fingolimod-p’s effects on central neurons (Foster 
et al., 2007). Fingolimod-p has been shown to have a direct effect on neurons. Previous 
studies in vitro and in vivo demonstrate that fingolimod-p acts on neurons to increase 
production of BDNF mRNA and protein (Deogracias et al., 2012, Doi et al., 2012). This 
effect appears to be specific for BDNF and does not affect the mRNA levels of other 
members of the neurotrophic factor family (Doi et al., 2012). Despite compelling 
evidence for a relationship between fingolimod-p and BDNF, the exact mechanism is not 
entirely understood. Deogracias et al., (2012) suggests fingolimod-p activates the MAPK 
signaling pathway resulting in phosphorylation of CREB and enhanced transcription of 
BDNF (Deogracias et al., 2012).  
 
S1PR in axons and neurite extension 
 While S1PRs are found in many tissues types, only S1P1R, S1P2R, S1P3R and 
S1P5R are found in neurons where they have been shown to be involved in cellular 
processes such as survival, migration, differentiation and process extension/retraction 
(Soliven et al., 2011). The S1P1R is important for neurite extension and retraction.  In 
terms of neurite extension and retraction, previous investigations show S1P1Rs are 
important for translocation of SphK1 to the plasma membrane where its substrate, S1P is 
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located. S1P can then activate the S1P1R, initiating Gi signaling. The interaction of these 
signaling pathways has been shown to regulate the activation of Rac, a small GTPase 
known to interact with the cytoskeleton and promote neurite outgrowth. These results 
were further supported by studies in which NGF induced neurite outgrowth was enhanced 
in response to S1P1R overexpression. Thus, there is evidence to suggest S1P1R is 
involved in neurite outgrowth (Toman et al., 2004) 
 
S1PR signaling   
S1PRs are G-protein coupled receptors that upon activation initiate canonical 
signaling pathways associated with Gi/0, Gq and G12/13 proteins. The S1P1R is 
associated with the Gi/0 proteins and downstream signaling pathways involving 
activation of PI3K, Ras and PLC activation of PKC and release of Ca2+ from IP3 sensitive 
stores. Activation of this signaling pathway is known to be associated with neurite 
extension in TrkA positive neurons (Toman et al., 2004, Sanchez et al., 2007, Yoon et al., 
2008) [Figure 1-6]. 
There is evidence for cross talk between S1PRs and tyrosine kinase receptors. 
However the exact mechanism by which this occurs is unknown. Investigations using 
PC12 cells containing S1P1Rs or cultured DRG cells support a relationship between 
S1P1R, TrkA and Rho GTPases; Rac and Rho, both of which have been implicated in 
cytoskeletal reorganization and neurite extension/retraction. In this model S1P1R 
containing cells exposed to NGF undergo enhanced neurite outgrowth via TrkA 
activation and subsequent stimulation of Sphk1. The result is activation of Rac, decreased 




TYROSINE KINASE RECEPTORS 
General characteristics of the Trk receptors 
Trk receptors were originally discovered from a colon carcinoma derived 
oncogene. Studies by Mitra et al. (1987), identified P70TRK as the gene product of the 
TRK oncogene. Further investigation found that this gene product is phosphorylated at 
tyrosine residues, a canonical characteristic of tyrosine kinase receptors (Mitra et al., 
1987).   
Further investigations of Trk receptors reveal vertebrates express three 
homologous Trk receptors: TrkA, TrkB and TrkC.  Each Trk receptor has a similar 
structure containing the following components: 1) an extracellular, ligand binding 
domain containing two immunoglobulin-like C2 domains, 2) a single pass 
transmembrane domain and 3) a cytoplasmic domain containing tyrosine kinase activity 
that functions as an autoregulatory loop. Additional tyrosine residues surrounding the 
kinase domain act as binding sites for adaptor proteins or enzymes (Ultsch et al., 1999). 
Activation of Trk receptors occurs in a two-step process. First, binding of the 
neurotrophin to the Trk receptor induces receptor dimerization. Second, the receptor 
autophosphorylates tyrosine residues. This allows the receptor to bind to enzymes and 
adaptor proteins important for the elicitation of intracellular signaling pathways (Ibanez 






Trk expression profiles in chicken DRG 
The expression profile of Trk receptors in chicken embryo, DRG neurons varies 
throughout development. Early DRG development (E2.5; HH15-16) is characterized by a 
small population of migrating NCC expressing only TrkC. TrkA and TrkB do not reach 
detectable levels until E2.75 (HH st. 18) (Rifkin et al., 2000). As development progresses 
over the next few days, the molecular profile changes such that TrkC becomes down-
regulated and TrkA and TrkB become upregulated (Rifkin et al., 2000).  
At E4.5 (HH st. 24-25) chicken DRG express Trk receptors in the following 
proportions: 23% TrkA, 27% TrkB and 63% TrkC. This time in development coincides 
with a peak time for neurogenesis as well as apoptosis. In one study Rifkin et al., (2000) 
attempted to quantify the numbers of mitotically active Trk positive neurons in DRG at 
E4.5. Analysis of one interior region of the DRG found no actively dividing TrkA or 
TrkB positive neurons but found 20% of TrkC positive neurons were actively dividing 
(Rifkin et al., 2000).  Comprehensive quantitative investigations of mitotically active, Trk 
expressing DRG neurons has not been accomplished.  
By E6, all Trk positive neurons have segregated into subpopulations based on Trk 
expression type and function. TrkA expressing DRG are involved in nociception and are 
restricted to small diameter neurons in the dorsal medial region of DRG. TrkB expressing 
DRG neurons are involved in mechanoreception and are restricted to medium diameter 
neurons in the ventral lateral region of the DRG, and TrkC expressing DRG neurons are 
restricted to large diameter neurons in the ventral lateral region of the DRG (Mu et al., 







TrkB is involved in many developmental and physiological processes. The 
majority of these actions are dependent upon the binding of the mature form of brain 
derived neurotrophic factor (BDNF) to the membrane proximal, immunoglobulin like, C2 
domain (Schneider and Schweiger, 1991, Urfer et al., 1995). This binding permits 
receptor dimerization and trans-autophosphorylation of tyrosine (Y) residues within the 
auto-regulatory loop (Peng et al., 1995). Phosphorylation of Y-residues outside of the 
auto-regulatory domain allows for docking of adaptor proteins which may then elicit the 
activation of three major intracellular signaling cascades: MAP-kinase pathway, PI3k 
pathway and PLC-γ pathway (Qian et al., 1998). 
 
Regulation of neurite outgrowth by TrkB 
TrkB is an important regulator of sensory neurite outgrowth. Previous work with 
neuroblastoma SH-SY5Y cells expressing TrkB exhibit enhanced neurite outgrowth in 
response to BDNF or synthetic TrkB antibodies designed to selectively activate TrkB 
receptors (Itoh et al., 2011). Further, DRG neurons in both developing systems and injury 
models exhibit enhanced neurite outgrowth in response to TrkB activation (Mu et al., 
1993, Runyan and Phelps, 2009).  
 Additionally, negative modulation of TrkB has been shown to suppress axon 
outgrowth and arborization. Protein tyrosine phosphatase Receptor Type O (PTPRO), a 
phosphatase known to act on Trk receptors suppresses axon arborization and outgrowth 
in TrkB positive sensory neurons via inhibition of BDNF induced autophosphorylation of 




TrkB splicing and expression patterns 
 
TrkB is a large transmembrane protein with complex splicing and expression 
patterns. Variations of the TrkB receptor include: the full length receptor, two isoforms 
with intact kinase domains lacking exon 16, two kinase deleted isoforms TrkB-T1 that 
lacks SHC binding sites and TrkB-SHC containing SHC binding sites (Eide et al., 1996, 
Ninkina et al., 1997).   
All isoforms of the TrkB receptor are expressed in the CNS, PNS and 
leptomeninges of the developing chicken embryo; however, the exact role each of these 
isoforms play in development is poorly understood. Competing theories suggest truncated 
TrkB receptors regulate neuronal responsiveness to neurotrophins or may serve a role in 
cell metabolism (Baxter et al., 1997). Still other studies suggest truncated forms of the 
TrkB receptor may act as a barrier to prevent diffusion of BDNF between developing 
networks of neurons (Biffo et al., 1995). 
The full length TrkB receptor is known to elicit the activation of multiple 
intracellular signaling pathways. The truncated isoforms lack much of the intracellular 
domain and thus are prevented from activating the intracellular signaling pathways 
classically associated with the full length TrkB receptor. Truncated TrkB receptors have 
been shown to regulate cytoskeletal changes in neurons independent of BDNF and to 
elicit the activation of Rho GTPases (Fenner, 2012). Whether truncated isoforms of TrkB 








TRKB SIGNALING  
 
TrkB signaling overview  
 
TrkB activation with BDNF results in receptor dimerization and trans-auto-
phosphorylation of tyrosine residues. This allows for docking of proteins on 
phosphorylated tyrosines and activation of three canonical intracellular signaling 
pathways: PLC-γ, MAPK and PI3K (Qian et al., 1998). The downstream effectors 
activated by these pathways include: 1) PLC-γ: release of intracellular Ca2+ from IP3 
sensitive stores and diacylglycerol (DAG)/ protein kinase C (PKC) signaling, 2) MAPK: 
activation of Ras, 3) PI3K: activation of AKT (Middlemas et al., 1994, Atwal et al., 
2000). The contribution of these signaling pathways to DRG axon extension in the 
developing longitudinal pathway is a major focus of this dissertation. 
 
Phospholipase C- γ (PLC-γ) signaling pathway  
 
Activation of TrkB with BDNF results in phosphorylation of Y816 and 
recruitment of PLC- γ to bind directly to the TrkB receptor (Huang and Reichardt, 2003). 
Activation of PLC- hydrolyzes Phosphoinositide (4,5)P2, resulting in the production of 
inositol tris-phosphate (IP3) and diacylglycerol (DAG). IP3 interacts with IP3 receptors on 
the endoplasmic reticulum (ER) to promote release of Ca2+ from internal stores. The 
result is activation of Ca2+ dependent enzymes such as Ca2+-calmodulin regulated protein 
kinase (CamkII) and cAMP response element binding protein (CREB) (Minichiello et al., 
2002) (Figure 1-7A). Previous studies suggest neurons depend upon activation of the 
PLC-γ signaling pathway for various cellular processes including axon outgrowth in 
model cell lines (Minase et al., 2010). 
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The importance of the PLC-γ pathway to neurite outgrowth is further highlighted 
by two lines of evidence. First, that in chicken embryo, DRG axons exhibit IP3R 
enrichment in axon growth cones (Itoh et al., 2011). Second, inhibition of downstream 
effectors such as IP3 receptor induced Ca
2+ release and Ca2+ induced Ca2+ release from 
intracellular stores attenuates neurite outgrowth (Stephens et al., 1994, Arie et al., 2009).  
 
Mitogen activated protein kinase (MAPK) signaling pathway 
  
The MAPK signaling pathway is a canonical pathway for the Trk receptor family 
and has been implicated in many developmental events including neurite outgrowth 
(Minichiello et al., 1998). Activation of TrkB with BDNF results in phosphorylation of 
Y490, a recruitment site for adaptor protein Shc. Upon binding to Y490 at its PTB 
domain, Shc auto-phosphorylates and recruits an additional adaptor protein Grb2. This 
adaptor is complexed with son of sevenless (SOS), a guanine nucleotide exchange factor 
that catalyzes the exchange of guanosine diphosphate (GDP) to guanosine triphosphate 
(GTP) on Ras and Rac (Nimnual et al., 1998). Activation of Ras can then activate 
additional signaling pathways including: PI3K signaling and the MAPK signaling leading 
to activation of ERK1/2 by Mek1 and Mek2. Erk1/2 have been shown to phosphorylate 
CREB (Huang and Reichardt, 2003) [Figure 1-7B].  
The MAPK signaling pathway is activated at early stages in chicken embryo 
development. Lunn et al, 2007 found ERK activity in the primitive streak and pre-
somatic mesoderm in chicken  (HH4-10) (Lunn et al., 2007). As development progresses, 
the MAPK pathway becomes abundantly expressed in the PNS where it is involved in 
development of glia, myelination and various stages of axon development (Newbern et 
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al., 2011). The exact role this signaling pathway plays in the development of DRG in 
vivo is not entirely understood.  
 
Phosphoinositide 3-kinase (PI3K) signaling pathway 
 
Endogenous activation of the PI3K pathway occurs in three major ways. First, 
PI3K signaling is initiated by Trk receptor activation and recruitment of adaptor proteins 
Shc, Grb-2 and Gab-1 (Liebl et al., 1997). Second, PI3K signaling is initiated 
independent of Trk receptors via Ras proteins (Holgado-Madruga et al., 1997). Finally, 
more recent findings suggest Neuronal tYrosine-phosphorylated Adaptor for PI 3-kinase 
(NYAP) activates PI3K signaling in developing neurons (Chu-Wang and Oppenheim, 
1978) [Figure 1-7C]. 
Activation of PI3K signaling through Trk receptors has been shown to regulate 
sensory neurite outgrowth in vitro. Mullen et al., (2012) show PI3K signaling through 
Trk receptors regulates neurite outgrowth in cochlear spiral ganglion explants (Ernfors et 
al., 1995a). Ras, a family of GTPases with close ties to the actin and microtubule 
cytoskeleton has been shown to activate PI3K signaling and neurite outgrowth 
(Hamburger and Levi-Montalcini, 1949). Finally, activation of P13K signaling through 
NYAP activates Rac, a member of the Rho family of GTPases known to relay signals to 
the cytoskeleton to promote actin polymerization. Additionally, NYAP interacts with 
Wiskott-Aldrich syndrome protein family verprolin homologous proteins (WAVE), a 
family of proteins known to influence the actin cytoskeleton through interaction with the 
Actin related protein 2/3 (ARP2/3) complex, a protein complex consisting of actin 
binding protein that associates with the actin cytoskeleton and initiate actin 
polymerization (Chu-Wang and Oppenheim, 1978, Wetts and Vaughn, 1998). Thus, there 
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is compelling evidence for the involvement of PI3K signaling in neurite outgrowth; 
however, the means by which PI3K signaling is initiated appears to be dependent upon 
cell type.  
 
P75 neurotrophin receptor 
The P75 neurotrophin receptor (P75NTR) is a member of the tumor necrosis 
factor (TNF) receptor superfamily. There are two isoforms of this receptor. The full 
length receptor, containing an extracellular, cysteine rich domain, a signal 
transmembrane domain and an intracellular death domain known to be involved in 
mediating an apoptosis signal. In contrast, the short isoform contains an extracellular 
domain lacking a cysteine rich domain, and thus lacks the ability to bind neurotrophins.   
The function of P75 neurotrophin receptor (P75NTR) in the developing nervous 
system is less well understood than the Trk receptors. Previous investigations suggest 
P75NTR regulates responsiveness to neurotrophins in neurons by acting as a co-receptor 
with other Trk receptors. These interactions may increase receptor binding affinity and 
enhance neurotrophin specificity (Hempstead et al., 1991, Benedetti et al., 1993, Verdi et 
al., 1994). 
Upon neurotrophin binding, the full length P75NTR may elicit intracellular 
signaling pathways associated with cell death, survival and cell cycle regulation such as: 
the MAPK signaling pathway. Additionally, full length P75NTR signaling has been 
shown to be important for axon elongation through interactions with RhoA, a subgroup of 
the Ras superfamily GTP binding proteins known to control actin organization. 
Yamashita et al., 1999 found activation of P75NTR with NGF decreased activation of 
Rho-A and increased axon elongation in chicken retinal ganglia neurons (Yamashita et 
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al., 1999).  These findings suggest P75NRT may contribute to axon extension in other 
ganglia as well.  
 
 
CALCIUM IN AXON OUTGROWTH 
 
Competing theories exist for the role Ca2+ in axon outgrowth. One theory suggests 
elevation in cytoplasmic Ca2+ levels results in cytoskeletal remodeling in the growth cone 
and neurite outgrowth (Lankford and Letourneau, 1989, Ohbayashi et al., 1998). 
Evidence in support of this theory stems from the observation that intracellular Ca2+ 
levels are significantly higher in growing neurites than in retracting or stopped neurites 
(Connor, 1986).  
The source from which this Ca2+ elevation is derived has been debated as well. 
Both release from intracellular stores and influx through voltage gated Ca2+ channels 
(VGCC) have been shown to contribute to increases in intracellular Ca2+(Anglister et al., 
1982, Doherty et al., 1991). Further evidence for the involvement of both of these sources 
comes from inhibition studies in which either inositol triphosphate receptor (IP3R) or 
VGCC were pharmacologically inhibited. Inhibition of Ca2+release from IP3 sensitive 
stores significantly attenuates neurite outgrowth in dissociated E10 DRG (Takei et al., 
1998). In addition, a similar effect can be seen with pharmacological inhibition of VGCC 
(Harper et al., 1994). While both of these mechanisms have been shown to contribute to 
transient elevations in intracellular Ca2+, there is compelling evidence suggesting that 
neurite outgrowth in early embryonic development relies more heavily upon IP3R 
mediated Ca2+ release, whereas later development may depend upon VGCC and 
ryanodine receptors (RYR) (Arie et al., 2009). 
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In contrast, competing evidence suggests that wide scale changes in intracellular 
Ca2+ do not affect axon morphology or outgrowth, but rather a Ca2+ set point must be 
maintained in order for neurite outgrowth to occur (Fields et al., 1993). Yet, additional 
theories suggest that small, localized changes and/or increases in Ca2+ cycling are 
required for axon outgrowth (Runyan and Phelps, 2009). 
Many of the discrepancies in the literature stem from the fact that work has been 
performed in different cell types which may contain different Ca2+ channel profiles both 
on the plasma membrane and intracellularly. The exact mechanisms used by developing 
afferents in the chicken embryo has yet to be determined.    
 
Calcium and BDNF  
BDNF is the only neurotrophin capable of elevating cytoplasmic Ca2+ and 
mediating Ca2+ transients in neurons (Berninger et al., 1993, Lang et al., 2007). BDNF 
transcription can be regulated by influx of Ca2+ through L-type VGCCs. Elevated levels 
of intracellular Ca2+ mediate phosphorylation and activation of cAMP response element 
binding protein (CREB). When inactive, CREB prevents BDNF transcription by binding 
to DNA. Phosphorylation of CREB relieves DNA binding allowing for recruitment of 
transcriptional machinery and the transcription of BDNF (Finkbeiner et al., 1997). How 
BDNF and Ca2+ then work to promote axon outgrowth during neurodevelopment in vivo 
is poorly understood.  
 
SUMMARY AND DISSERTATION AIMS 
A simple reflex is the result of an elaborate set of events that begin during early 
development. Underlying the formation of reflexes is communication between multiple 
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segments of the spinal cord. This is made possible by primary sensory afferent extension 
in the longitudinal pathway driven by signaling that occurs at the growth cone of these 
axons. 
In this work, DRG axon growth is studied in situ and is therefore influenced by 
the intrinsic and extrinsic factors and guidance cues that are endogenously affecting 
afferent growth.  The overarching goal of this work was to understand the endogenous 
regulation of afferent extension in the longitudinal pathway. To address this question we 
focused on the contributions of BDNF and S1P1Rs to afferent extension in the 
longitudinal pathway. Our hypothesis was that fingolimod-p, an S1P1R agonist, enhances 
afferent extension through a BDNF related mechanism. Given our observations that 
fingolimod-p enhances afferent extension in the longitudinal pathway through BDNF, we 
then sought to investigate the contributions of BDNF’s receptor, TrkB, and the 
endogenous signaling pathways associated with TrkB. Our hypothesis was that TrkB 
regulates DRG afferent extension through activation of the PLC-γ signaling pathway. 
Ultimately, this work provides evidence for a mechanism that regulates afferent 
extension in the longitudinal pathway. This work proposes a mechanism involving S1P1R 
and TrkB.  We propose fingolimod-p, through activation of the S1P1R, promotes BDNF 
release from neurons. BDNF may then act via an autocrine mechanism to enhance 
afferent extension in the longitudinal pathway via activation of TrkB and release of Ca2+ 
from IP3 sensitive stores via activation of the PLC-γ signaling pathway. Unlike other 
studies, this body of work provides a mechanism for growth that is occurring in situ, and 
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Figure 1-1. DiI label in DRG in in situ preparation. A. E5 (HH st. 25) chicken embryo 
from the dorsal perspective. T3/T4 DRGs have been labeled with DiI. Scale bar = 
200µm. Picture provided by Danielle Robinson. B. Multiphoton image of E5 (HH st.25) 
chicken embryo with T3/T4 DRG labeled with DiI. Primary sensory afferents can be seen 
growing in the longitudinal pathway. Scale bar = 200µm. Picture provided by Danielle 
Robinson C. Transverse section of E5 (HH st.25) chicken embryo. DiI label in the DRG 
(right) labels both the central and peripheral branches of the DRG neuron. DiI label 
placed distally to the DRG shows that the extent of the peripheral process is contained 
within the preparation and thus has not been damaged. Scale bar = 200µm. Picture 






Figure 1-2. Primary sensory afferent growth in the chicken embryo from the 
longitudinal perspective. A. E3 (HH st. 19; 72 hours) primary afferents extend towards 
the developing spinal cord. B. E5 (HH st.25; 120 hours) afferents have entered the DREZ 
and bifurcated along the longitudinal axis of the spinal cord to establish the longitudinal 
pathway. C. E8 (HH st.34; 192 hours) primary afferents branch ventrally to invest into 















Figure 1-3.  Organization of the axon growth cone. Contained within the axon shaft 
are microtubules organized in a parallel arrangement by association with MAPs. The 
growth cone is located at the distal most aspect of the axon. Within the growth cone are 
three domains: the central (C) domain, the transition (T) domain and the peripheral (P) 
domain. The C-domain contains de-fasciculated microtubules that may extend into the T-
domain. The T domain, contains arc-actin arranged in a perpendicular orientation to the 
filopodia of the P-domain. The primary purpose of the T-domain is to corral de-
fasciculated microtubules. The P domain contains two distinct features: the filopodia 





















Figure 1-4. Cytoskeletal dynamics during axon growth.  A. Axon outgrowth begins 
with protrusion of F-actin containing filopodia and lamellar structures located between 
adjacent filopodia. Microtubules (green) are coralled together in parallel arrangements by 
MAP (purple circles). B. Following protrusion, microtubules infiltrate the P-domain. 
During the engorgement period, microtubules translocate vesicles to the P-domain. C. 
Consolidation is marked by F-actin depolymerization and membrane shrinkage away 























Figure 1-5. Summary of molecular factors influencing afferent axon extension, 
retraction, attraction and repulsion. Factors influencing axon extension include: 
neurotrophic factors: BDNF and NGF and elevation of intracellular Ca2+. In contrast, 
factors that prevent axon extension and/or promote axon retraction include: activation of 
adenylate cyclase and decreases in intracellular Ca2+. In terms of directional growth, 
factors that contribute to axon attraction include Netrin interactions with DCC receptors, 
SHH interactions with Patched receptors and smoothened and increases in intracellular 
Ca2+. In contrast, factors contributing to axon repulsion include: Netrin interactions with 
Unc receptors, Semaphorin interactions with Plexin receptors and decreases in 








Figure 1-6. S1P1R signaling. Endogenous activation of S1P1R occurs through 
interaction with S1P. Exposure to S1P1R agonists, fingolimod-p or SEW2871 activate the 
receptor. Activation of S1P1R elicits the activation of PI3K signaling, activation of RAS 
and activation of PLC-β, leading to cleavage of PIP2 into DAG and IP3 leading to release 



























Figure 1-7. Intracellular signaling pathways elicited by activation of TrkB with 
BDNF. Activation of TrkB with BDNF leads to trans-autophsophorylation of the TrkB 
receptor resulting in the activation of three canonical signaling pathways. 1-7A. 
Activation of the PLC-γ begins with phosphorylation on tyrosine (Y) residues on TrkB. 
This results in recruitment of PLC-γ binding to phosphorylated Y. Activation of PLC-γ 
leads to hydrolysis of PIP2 into DAG and IP3. IP3 activates IP3Rs on the ER, mediating 
release of Ca2+ from IP3 sensitive stores. Ca
2+ may then activate kinases such as CAM, 
CAMK and CAMKK, ultimately leading to phosphorylation of CREB and alteration in 
gene transcription 1-7B. Activation of the MAPK signaling pathway begins with 
phosphorylation of Y516 on TrkB. This leads to recruitment of adaptor proteins Shc, 
Gab1/2 and Grb2. Grb2 is associated with a GTP exchange factor, SOS which removes 
GDP from Ras, activating it with GTP. Ras then activates the remainder of the MAPK 
signaling pathway, including Raf, MEK1/2, ERK1,2 and Rsk. Rsk phosphorylates CREB 
within the nucleus to alter gene transcription. 1-7C. Activation of the PI3K signaling 
pathway occurs through three means. Phosphorylation of Y residues leads to recruitment 
of adaptor proteins that activate PI3K which in turn, may phosphorylate AKT. P-AKT 
can then alter gene transcription in the nucleus. Secondly, PI3K may be activated by GTP 
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Primary sensory afferents extend along the longitudinal axis of the developing 
spinal cord between embryonic day 4-8 (E4-8) to establish the longitudinal pathway. An 
understanding of the endogenous factors that regulate afferent extension in the 
developing longitudinal pathway is important for understanding the mechanisms that 
regulate development of the intersegmental communication that underlies reflex 
formation.  
In this study we used the chicken embryo to look at the effects of brain derived 
neurotrophic factor (BDNF), a neurotrophic factor known to enhance neurite outgrowth 
in vitro, on afferent extension in the longitudinal pathway. We then investigated the 
effects of fingolimod-p, a sphingosine 1-phosphate receptor (S1PR) agonist known to 
enhance BDNF mRNA and protein production in embryonic systems. 
We found BDNF enhances DRG axon extension whereas inhibition of BDNF 
attenuates axon extension. Additionally, fingolimod-p increases BDNF mRNA 
production two fold and enhances primary afferent axon extension through the S1P1R. 
Collectively, these results reveal an endogenous mechanism for DRG axon extension 
within the developing longitudinal pathway that requires BDNF and S1P1Rs. 









Fingolimod-p is a sphingosine 1-phosphate receptor (S1P1R) agonist previously 
shown to be highly efficacious in ameliorating the symptoms of experimental 
autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, and in the 
treatment of relapsing remitting forms of multiple sclerosis (RRMS) (Fujino et al., 2003, 
Agius et al., 2014). In clinical trials, patients with RRMS treated with fingolimod-p 
(0.5mg or 1.25mg) had fewer inflammatory brain lesions as assessed by Gadolinium (Gd) 
enhanced lesions on T2 MRI, slower rates of brain volume loss and decreased Extended 
Disability Status Scale (EDSS) score (Kappos et al., 2006, Kappos et al., 2010, Radue et 
al., 2012). 
The exact mechanism by which fingolimod-p ameliorates RRMS is not entirely 
understood. Within the immune system, two mechanisms of action have been proposed. 
First, that fingolimod-p binds to S1P1Rs resulting in receptor internalization, 
ubiquitination and degradation. The result is inhibition of S1P1R dependent lymphocyte 
egress from lymphoid tissues (Pham et al., 2008). A second proposed mechanism of 
action is that fingolimod-p binds to S1P1Rs on endothelium resulting in closure of 
lymphocyte egress portals (Wei et al., 2005).  
Other studies indicate fingolimod-p has direct effects on neurons. Previous work 
suggests fingolimod-p has neuroprotective qualities mediated by activation of the S1P1R 
and production of trophic factors (Meng and Lee, 2009, Deogracias et al., 2012, Doi et 
al., 2013). A relationship between fingolimod-p and brain derived neurotrophic factor 
(BDNF) within neurons has been established. Deogracias et al., (2012) showed that 
fingolimod-p increases BDNF mRNA and protein production within E16.5 mouse 
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cortical neurons but not glial cells (Deogracias et al., 2012). Additionally, Doi et al., 
(2013) found fingolimod-p exerts a neuroprotective effect on cortical neurons through 
enhancement of BDNF and TrkB-ERK signaling (Doi et al., 2013). Both of these studies 
examined the neuroprotective effects of fingolimod-p in the context of neurodegenerative 
disease.  
BDNF is expressed in chicken during early development (Baig and Khan, 1996). 
While originally identified as a survival factor, it has since been shown to have many 
functions throughout development including neurite outgrowth in dorsal root ganglia 
(DRG) cells in vitro (Barde et al., 1982, Lindsay et al., 1985a, Davies et al., 1986, Wright 
et al., 1992).  
In this study we used an embryonic system to assess the effect of fingolimod-p on 
primary afferent neuron axon extension in the longitudinal pathway. In the chicken 
embryo, primary sensory afferents develop in a three step process that begins at 
embryonic day (E3) with afferents extending towards the spinal cord. At E4 axons enter 
the dorsal root entry zone (DREZ) and bifurcate to extend axons in the rostral to caudal 
direction to establish a longitudinal pathway before turning ventrally to invest within the 
grey matter of the spinal cord at E8 (Coutinho-Budd et al., 2008, Robinson et al., 2015). 
This developmental pathway is essential for intersegmental and intrasegmental 
communication between multiple segments of the spinal cord and is essential for the 
development of reflexes. Importantly, at this stage in development, glia are not present in 
the DREZ or longitudinal pathway and DRG cell bodies and axons are unmyelinated. 
This is because gliogenesis does not begin until E6 and myelin formation does not begin 
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until E13 (Keirstead et al., 1992, Zhou et al., 2001). Thus, the effects of fingolimod-p on 
axons can be directly addressed.  
In this study, we investigate the effects of fingolimod-p on DRG neuron axon 
extension within the longitudinal pathway of the developing spinal cord. These results 
show fingolimod-p enhances axon extension via an S1P1R and BDNF dependent 
mechanism. 
 
Materials and Methods 
Animals  
Fertilized eggs (Charles River Sunrise Farms; Premium SPF standard fertile eggs) 
were stored at 15°C until incubation at 37.5°C. Developmental stage was determined by 
criteria established by Hamburger and Hamilton (Hamburger and Hamilton, 1951). 
Embryos were removed from their embryonic sac, decapitated and eviscerated in cold 
artificial cerebral spinal fluid (ACSF: 124 mM NaCl, 2.5 mM KCl, 1.3 mM MgCl2, 1.25 
mM KH2PO4, 26mM NaHCO3, dH2O, 2.5 mM CaCl2, 20mM D-glucose). ACSF was 
bubbled with 95% O2/5% CO2 to maintain pH: 7.2-7.4).  
 
Immunohistochemistry  
Antibody and Drug concentrations  
Rabbit α S1P1R antibody (Cayman chemical) and sheep α BDNF antibody 
(Millipore) were diluted in phosphate buffered saline (PBS) to 1:500 and 1:1000, 
respectively. Specificity for the rabbit α S1P1R in chicken was established by (Crousillac 
et al., 2009). Specificity of sheep α BDNF was previously established for chicken (Taylor 
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et al., 2012).  Additionally, a mouse α Neurofilament SMI 31 antibody (Covance) was 
used to stain medium and heavy weight neurofilaments and a rabbit α neurofilament-M 
C-terminal (Millipore) for medium sized neurofilaments. Secondary antibodies used were 
goat α rabbit IgG alexa 488 (Invitrogen), rabbit α sheep IgG 488 (Millipore), goat α 
mouse IgG 488 (Millipore) and goat α rabbit IgG cy3 (Jackson laboratories). No primary 
controls were performed with all immunohistochemistry assays. 
BDNF function blocking activity was established for the sheep α BDNF antibody 
at 0.5µg/µl (Taylor et al., 2012). Sheep IgG (Sigma Aldrich) was used in control 
experiments at 0.5 µg/µl. Human recombinant BDNF (R&D) was dissolved in dH20 to a 
500ng/ml stock solution. Fingolimod-p phosphate (Echelon) was dissolved in 100% 
MeOH to make a 2.5mM stock solution. The S1P1R agonist, SEW2871 (Tocaris), was 
dissolved in 100% DMSO to make a 10mM stock solution. The S1P1R antagonist, W123 
(Cayman chemical), was dissolved in 100% DMSO to 1mM stock solution. On day of 
use, all drugs were diluted in ACSF to make a final concentrations along with 1% 
DMSO.  
Every experiment contained an internal control containing a group of chicken 
embryos that were exposed for 5 hours to a vehicle control (VC) solution consisting of 
ACSF and a final concentration of 1% DMSO. The length of the axons from each group 
of embryos exposed to a drug treatment was compared to its own unique VC treatment 
group. This was done to control for potential minor fluctuations in incubator temperature 






Tissue preparation and immunohistochemistry 
Dissected tissue was immersed in 4% paraformaldehyde overnight and 
equilibrated in 30% sucrose in phosphate-buffered saline. Tissues were then frozen in 
optimal cutting temperature compound (O.C.T) (Tissue Tek) and cryo-sectioned into 
20µm transverse sections. Sections were incubated in primary antibody overnight at 4°C 
followed by incubation with secondary antibodies for 1hr at room temperature. Sections 
were rinsed and cover slipped with Ctiifluor AFI (Ted Pella Inc.). Tissues were imaged 
with a Microphot-SA (Nikon) fluorescent microscope. 
 
Afferent labeling, imaging and axon measurement 
120 hour old embryos (Embryonic day 5 (E5), HH st.25) were sacrificed, 
decapitated and eviscerated. A capillary pipet containing 1,1’dioctadecyl-3,3,3’3’-
tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes) was placed into DRG 
at thoracic level 3 or 4 (T3 or T4) on both sides of the spinal cord (Robinson et al., 2015). 
DiI was applied using a picospritzer III with compressed nitrogen pressure (1ms; 40pA). 
Immediately after labeling, tissue was rinsed in sterile ACSF and transferred to a 0.4µm 
Millicell in a 35mm sterile culture dish and treated with a drug solution or a control 
solution (ACSF and 1% DMSO). Tissue was then incubated for 5 hrs at 37°C in 5% CO2. 
Following incubation, tissue was fixed in 4% paraformaldehyde.  Tissue was imaged with 
a BioRad Multiphoton Microscope. DRG axon length was measured using Volocity 
software (PerkinElmer). Measurements were made from the middle of the DREZ where 
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axons bifurcate to the most distal end of the axon in both the rostral and caudal 
directions. The z series images were flattened using Image J.  
RNA extraction 
T2 through T5 DRG from HH st.25 chicken embryos were isolated following 5 
hour treatment with either ACSF (1% DMSO) or fingolimod-p [250µm] (1% DMSO). 
DRG were flash frozen in dry ice and frozen overnight at -80°C. Total RNA was 
extracted using TRI reagent (Sigma Aldrich).  
 
Quantitative real time-PCR  
For each sample, 1µg was reverse transcribed using Multiscribe reagent 
containing d-NTPs and random hexamers. E12 chicken brain served as a positive control. 
The cDNA (1µl) was amplified using TaqMan fast advanced master mix reagents 
(Applied Biosystems) using primers for BDNF from a TaqMan gene expression assay 
(Applied Biosystems). Chicken S17 ribosomal binding protein [CHRPS] was used as the 
constitutive control gene. Primers for CHRPS were forward 5’-
AACGACTTCCACACCAACAA-3’ and backwards 3’-AAATTGCATCCGGCTATGA-
5’ with probe 5’-CGCCATCATCCCCAGCAAGA-3’. After a 20 second 95°C heat 
activation step, cycling parameters were as follows: 95°C for 3 seconds, 60°C for 30 
seconds and 72°C for 30 seconds. This was repeated 40 times.  
 
Statistical analysis  
Groups were compared using a one-way analysis of variance (ANOVA) or a 
student’s T test (two tailed). In the event of detected significance, Tukey’s Post-hoc-Test 
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was used to determine groups significantly different from each other. All calculations 
were made using PRISM scientific graphing software from Graphpad (GraphPad 
Software, San Diego). Statistical significance was set at p<0.05. 
 
Results 
The current study sought to assess the role of fingolimod-p on DRG axon 
extension within the developing longitudinal pathway of the spinal cord. To address this 
question, all embryos were studied at HH st.25, a time point at which thoracic primary 
sensory afferents have bifurcated and are extending processes along the longitudinal axis 
of the developing spinal cord (Coutinho-Budd et al., 2008). At this time point, these 
axons have not yet turned ventrally to invest into the grey matter of the cord, thus making 
HH st.25 an ideal point to investigate regulation of extension within the longitudinal 
pathway (Eide and Glover, 1995, Coutinho-Budd et al., 2008) (Figure 2-1 A,B). 
 
Expression of S1P1R and BDNF in DRG and DREZ in HH st.25 chick embryo 
We first sought to determine if S1P1R and BDNF were expressed at HH st.25. 
Immunoreactivity for S1P1R and BDNF was observed in DRG and DREZ at HH st.25 
[Figure 2-2A-D]. Immunoreactivity for BDNF and heavy and medium chain 
neurofilament, a marker for axons, demonstrates considerable overlap of the two labels at 
HH st.25 (Figure 2-2E-G). Additionally, immunoreactivity for S1P1R and neurofilament 





S1P1R agonists enhance DRG axon extension while S1P1R antagonists inhibit axon 
extension. 
To determine whether S1P1R agonists affected afferent extension we exposed our 
preparation to S1P1R agonists fingolimod-p and SEW2817. Afferent extension was 
enhanced in fingolimod-p [250µm] treated embryos and in SEW2871 [100µm] treated 
embryos [Figure 2-3A, B].  Additionally, S1P1R antagonist W123 [25µm] attenuated 
afferent extension [Figure 2-3B]. Given that both fingolimod-p and SEW2871 enhance 
afferent extension, we then asked whether combined exposure to fingolimod-p and 
SEW2817 or fingolimod-p and W123 affected afferent extension. We found fingolimod-
p [250µm] and SEW2817 [100µm] enhanced afferent extension, but the extension was 
not different for either agonist alone whereas addition of fingolimod-p [250µm] and 
W123 [25µm] together attenuated afferent extension to levels of W123 alone [Figure 2-
3C]. 
 
Addition of exogenous BDNF enhances afferent extension whereas blocking BDNF 
attenuates afferent extension.  
To determine if BDNF regulates primary afferent extension, we tested the effects 
of treatment with BDNF or a function blocking antibody against BDNF. Treatment with 
exogenous BDNF (75-100 ng/ml) resulted in an increase in DRG axon extension [Figure 
2-4A]. Conversely, inhibition of endogenous BDNF with αBDNF function blocking 






Fingolimod-p’s effect on afferent axon extension requires BDNF  
 To determine whether fingolimod-p regulated BDNF mRNA production in DRG 
neurons we performed qPCR analysis on DRG from E5 chicken embryos following 
fingolimod-p treatment. We found a two fold increase in BDNF mRNA levels in 
fingolimod-p [250µm] treated embryos [Figure 2-5A]. Given the finding that fingolimod-
p enhances BDNF mRNA production, we then asked whether BDNF was required for 
fingolimod-p enhanced afferent extension. Combined treatments with fingolimod-p 
[250µm] and a function blocking antibody to BDNF (5ng/ml) resulted in significant 
attenuation of afferent extension in the longitudinal pathway [Figure 2-5B].   
 
Discussion 
In this study we investigated the regulation of primary sensory afferent axon 
extension in the longitudinal pathway of the developing spinal cord. The primary finding 
of this investigation is that DRG afferent extension is enhanced by a mechanism 
requiring S1P1R activation and BDNF.   
There are many chemoattractive and chemorepellant signals present within the 
developing embryo. For instance, netrins and semaphorins have been shown to be 
expressed in developing spinal cord grey matter between E5-7.5 when afferents are 
extending within the longitudinal pathway. Here, both netrins and semaphorins act as 
repulsive guidance cues, preventing afferents from entering into the grey matter of the 
developing spinal cord (Watanabe et al., 2006, Liu et al., 2014). It is likely that S1P1R 
activation and subsequent augmentation of BDNF signaling influences parallel signaling 
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mechanisms. Interestingly, afferents were never observed to deviate outside of the 
longitudinal pathway or prematurely turn towards the grey matter of the cord in response 
to any of the drug treatments in this investigation.    
Precedent for this work derives from previous investigations of fingolimod-p, an 
S1P1R agonist shown to enhance BDNF mRNA and protein production in embryonic 
cortical neurons (Deogracias et al., 2012, Doi et al., 2013). A functional role for the 
S1P1R has been investigated, and previous studies find that activation of S1P1R with its 
endogenous agonist, sphingosine 1-phosphate (S1P), influences neuronal morphology, 
neurite retraction and neurite extension (Sato et al., 1997, Toman et al., 2004). Our 
findings support previous studies, as we show activation of the S1P1R with fingolimod-p 
or SEW2871 enhances axon extension. Agonists, fingolimod-p and SEW2871 activate 
the S1P1R through different mechanisms. Fingolimod-p is known to bind to S1P1Rs and 
induce receptor internalization and degradation whereas SEW2871 promotes S1P1R 
internalization and recycling back to the cell membrane (Jo et al., 2005, Ng et al., 2007). 
Despite the difference in mechanism, a similar effect was observed with application of 
either pharmacological agent. Additionally, we show inhibition of S1P1R with W123 
attenuates DRG axon extension. These findings suggest that S1P1R acts as a regulator of 
DRG axon extension within the developing longitudinal pathway.  
A significant relationship has been established between fingolimod-p and BDNF, 
a neurotrophic factor shown previously to promote neurite outgrowth in developing 
chicken DRG when used at [50ng/ml] (Lindsay et al., 1985b). We found higher 
concentrations of BDNF [75-100 ng/ml] were required to enhance DRG axon extension 
in our preparation. This discrepancy is most likely due to the additional tissue present 
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within the experimental preparation. Additionally, previous work by Davies et al., (1986) 
found neurite outgrowth was enhanced in E5-6 DRG explants with [100ng/ml] of BDNF. 
An explant preparation is a closer representation of our in situ preparation and is more 
consistent with our findings. A functional role for endogenous BDNF in DRG axon 
extension in the longitudinal pathway was further supported by the attenuating effect on 
axon extension in response to αBDNF function blocking antibody. 
The mechanism by which BDNF promotes afferent extension within the 
longitudinal pathway was not investigated. One possibility is that BDNF is secreted from 
the DRG afferent and through autocrine and paracrine signaling activates its high affinity 
receptor, tyrosine kinase receptor B (TrkB). This is a likely possibility as TrkB mRNA 
and protein are known to be expressed in primary sensory afferents in E5 HH st.25 
chicken (Dechant et al., 1993, Straub et al., 2007).  
Previous investigations found pM-nM concentrations of fingolimod-p increased 
BDNF mRNA and protein production in embryonic cortical neurons in mouse 
(Deogracias et al., 2012, Doi et al., 2013). In line with these findings we found 
fingolimod-p [250µm] increased BDNF mRNA levels in our system by two fold. This led 
us to assess whether BDNF protein levels were elevated in response to exposure to 
fingolimod-p. However, ELISA assays were inconclusive as BDNF concentrations 
detected from control and fingolimod-p treated embryos were below the level of 
detection for available ELISA kits (data not shown).  
Whether BDNF is being transcribed and translated in the growth cone or the cell 
body in response to fingolimod-p exposure could not be determined in this investigation. 
Previous investigations suggest transcription and translation occur locally within the 
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growth cone (Jung et al., 2014). Whether BDNF is transcribed and translated within the 
growth cone is unknown. A more likely possibility is that fingolimod-p acts on S1P1Rs 
on the cell body and BDNF is transcribed and translated within the cell body. 
Anterograde transport can then move BDNF from the cell body to the afferent growth 
cone. Anterograde transport of BDNF has been previously calculated in E18 rat 
hippocampal neurons to be 1.49µm s-1  (Lo et al., 2011).  In this investigation, afferents 
grew between 500-1000µm along the longitudinal pathway. The distance from the DRG 
cell body to the longitudinal pathway is 80-100µm. Thus, in a 5 hour incubation period, 
BDNF could readily be anterogradely transported to the growth cone at the most distal 
end of the growing axon.    
Given both S1P1R agonists and BDNF enhance afferent extension and that the 
S1P1R agonist, fingolimod-p enhances BDNF mRNA, we next sought to investigate 
whether enhancement of afferent extension by exposure to fingolimod-p requires BDNF. 
Our findings suggest that the fingolimod-p effect on afferent extension is the result of its 
effect on BDNF production.  
Ultimately, these findings provide evidence for a mechanism that enhances DRG 
axon extension in the developing longitudinal pathway [Figure 2-6].  This mechanism 
can be pharmacologically manipulated within a live in situ preparation. Additionally, 
these findings suggest the disease modifying effects of fingolimod-p in RRMS may be 
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Figure 2- 1. DRG axons extend within the longitudinal pathway of the 
developing chicken spinal cord at E5, HH st.25. A. Multiphoton image of DiI 
labeled primary sensory afferents from HH st.25 chicken embryo. Longitudinal 
extension of primary sensory afferents is observed and measured from the point 
of axon bifurcation at the DREZ to the most distal axon tip. Scale bar =100μm. 
B. Schematic representation of longitudinal extension of primary sensory 








Figure 2- 2. BDNF and S1P1R expression in E5 HH st.25 chicken embryos. 
Transverse sections (20µm). A. BDNF immunoreactivity in DRG, DREZ and SC B. 
S1P1R immunoreactivity in DRG, DREZ and spinal cord (SC) C. Neurofilament 
(Covance) immunoreactivity in DRG axons and DREZ. D. No primary control. E-G. 
BDNF immunoreactivity (green) and neurofilament (red) immunoreactivity are 
coexpressed (yellow) in DRG. H-K. S1P1R (green) and neurofilament (red) 
immunoreactivity expressed in DRG and spinal cord. K. Higher magnification insert 
from S1P1R- neurofilament merge. Individual cell bodies contain immunoreactivity for 
S1P1R (green) and  neurofilament (red). L. No primary control. Scale bar in figure 2D= 
50µm and pertains to figures 2A-D. Scale bar figure 2L= 50µm and pertains to figures 
2E-J (scale bar is 2K= 10µm). SC= spinal cord. 
NF1= mouse α Neurofilament SMI 31(Covance) was used to stain medium and heavy 
weight neurofilaments. NF2= rabbit α neurofilament-M C-terminal (Millipore) for 


















Figure 2-3. S1P1R agonists enhance afferent extension whereas S1P1R inhibitor 
attenuates afferent extension. A. Afferent extension was enhanced following treatment 
with fingolimod-p [200-250μM] (n>6). Each fingolimod-p treatment was completed as a 
separate experiment and compared to a control group of embryos treated with ACSF+ 1% 
DMSO (student’s t-test, two tailed; p<0.05). B. S1P1R agonist, SEW2871 [100µM] (n>4) 
promotes DRG axon extension, whereas S1P1R antagonist W123 [25µM] decreases DRG 
axon extension (n>9). Experiment comparing VC to SEW2817 exposure was done 
separately from experiment comparing VC to W123 exposure.  C. Addition of both 
agonists fingolimod-p [250µM] and SEW2817 [100µM] enhances DRG axon extension 
(n>5) while addition of fingolimod-p [250µM] and W123 [25µM] together decrease axon 
extension (n>6). Experiments comparing VC to fingolimod-p [250µM] and SEW2817 
[100µM] was done separate from experiments comparing VC to fingolimod-p [250µM] 
and SEW2817 [100µM]. Significance was determined using a student’s t test (two 



















Figure 2-4. BDNF enhanced afferent extension whereas blocking BDNF attenuated 
afferent extension A. Primary afferent extension is enhanced with exposure to BDNF 
[75ng/ml ] and BDNF [100ng/ml ] treatment (n>4). Each BDNF treatment was 
completed as a separate experiment and compared to a separate group of embryos treated 
with ACSF + 1% DMSO. Significance was determined using a student’s t-test (two 
tailed). B. αBDNF [5µg/ml] function blocking antibody attenuate axon extension 
compared to VC or IgG control [5µg/ml] (n>6). Significance was determined using an 



























Figure 2-5. Fingolimod-p requires BDNF to enhance afferent extension. A. BDNF 
mRNA is elevated two fold in response to fingolimod-p [250µm] treatment compared to 
vehicle control (n>8). BDNF mRNA was compared relative to housekeeping gene 
CHRPS. Significance was determined using a student’s t-test (two tailed). B.  DRG axon 
extension was attenuated with fingolimod-p [250μM] and αBDNF[5µg/ml] treatment 


































Figure 2-6.  Model for enhanced afferent extension following exposure to 
fingolimod-p. Fingolimod-p activates the S1P1R in the cell body of the DRG neuron. 
Through an unknown mechanism, S1P1R activation enhances BDNF mRNA transcription 
and translation of BDNF protein within the cell body. BDNF may then be anterogradely 
transported to the growth cone where it is released to act on TrkB on the same or 
neighboring growth cone. The result is enhancement of afferent extension in the 
longitudinal pathway. 
*Occurs via an unknown mechanism 
**Occurs in axon growth cone 
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The anatomical pathway taken by developing dorsal root ganglia (DRG) axons to 
make connections with the central nervous system has been previously characterized. 
However, the endogenous mechanisms utilized by these axons to extend along the 
longitudinal axis through multiple segments of the developing spinal cord is poorly 
understood. This study investigates the role of TrkB in the growth of DRG axons along 
the longitudinal axis of the developing spinal cord. DRG axons growing along this axis 
are confined within a longitudinal pathway until they turn ventrally to make connections 
with neurons and interneurons within the grey matter of the spinal cord. It is this growth 
pattern that underlies the intersegmental communication required for reflex formation. In 
this investigation we found TrkB regulates DRG axon extension by the activation of 
phospholipase C-gamma (PLC-γ) signaling pathway and subsequent release of Ca2+ from 
IP3 sensitive stores stores. This work provides evidence for a mechanism for endogenous 













Introduction   
Primary sensory afferents establish connections to the grey matter of the spinal 
cord in a three step process. In the chicken thoracic spinal cord, at embryonic day 3 (E3) 
(Hamburger and Hamilton (HH) stage (st) 19), dorsal root ganglia (DRG) neurons extend 
processes centrally into the developing spinal cord. At E4.5, these axons bifurcate to form 
a T shape. Between E4.5 and E8, axons extend along the rostral to caudal axis to 
establish the longitudinal pathway. Finally, at E8, DRG axons simultaneously invest into 
the grey matter of the spinal cord. The result is the establishment of intrasegmental and 
intersegmental connections with neurons and interneurons within the developing spinal 
cord (Eide and Glover, 1995, Coutinho-Budd et al., 2008). Longitudinal extension of 
DRG axons along multiple segments of the spinal cord is essential for the establishment 
of intersegmental communication and subsequent coordination of reflexes (Sprague, 
1958). Previous studies suggest an endogenous growth factor, brain derived neurotrophic 
factor (BDNF) regulates axon growth in the longitudinal pathway (McNamara et al., 
2015).  
Tropomyosin receptor kinase B (TrkB), the high affinity receptor for BDNF, is a 
good candidate for the regulation of DRG axon extension in the longitudinal pathway. 
TrkB mRNA has been detected within chicken DRG beginning at E4.5 and protein 
immunoreactivity has been detected in neurons at developmental stages that coincide 
with longitudinal extension of DRG axons (Dechant et al., 1993, Baig and Khan, 1996, 
Straub et al., 2007).  
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Activation of TrkB with BDNF elicits three canonical signaling pathways: PLC-γ 
dependent generation of IP3 and diacylglycerol (DAG), mitogen activated protein (MAP) 
kinase cascade leading to activation of Ras and the phosphatidyl inositol-3 (PI3)-kinase 
stimulation of Akt (Middlemas et al., 1994).  
The following study investigates an endogenous mechanism regulating primary 
sensory afferent extension within the longitudinal pathway of the developing spinal cord. 
In this work, we demonstrate stimulation of TrkB with BDNF regulates DRG axon 
extension by PLC- γ signaling.  
 
Materials and Methods 
Animals  
Fertilized eggs (Charles River Sunrise Farms; premium SPF standard fertile eggs) 
were stored at 15°C.  Incubation time was 120 hours at 37.5°C. Developmental stage was 
determined by criteria established by Hamburger and Hamilton 1951 (Hamburger and 
Hamilton, 1951). At 120 hours embryos were removed from their in ovo environment 
where they were decapitated and eviscerated in cold artificial cerebral spinal fluid 
(ACSF: 124 mM NaCl, 2.5 mM KCl, 1.3 mM MgCl2, 1.25 mM KH2PO4, 26 mM 
NaHCO3, 2.5 mM CaCl2, 20 mM D-glucose dissolved in double distilled H2O). ACSF 







Antibody and Drug concentrations  
Table 3-1. Antibodies used in this work: 
Antibody Company  Concentration 
Rabbit αTrkB IgG Dr. Louis Reichardt; UCSF 
(von Bartheld et al., 1996) 
[1:2000] 
Goat α rabbit Alexa Fluor 
488 
Invitrogen [1:500] 
Rabbit IgG  Sigma Aldrich 100ng/ml 
 
Table 3-2. Drugs used in this work: 
Drug Company  Stock solution/solvent 
K252a Cayman Chemical 100mM (DMSO) 
Human recombinant 
BDNF 
R&D 500ng/ml (dH2O) 
U73122 Tocaris 2mM (DMSO) 
Xestospongin-C (Xe-C) Tocaris  2mM (DMSO) 
BAPTA-AM Cayman Chemical  50mM (DMSO) 
1-oleoyl-2-acetyl-sn-
glycerol (OAG) 
Sigma Aldrich 50mM (DMSO)  
Bisindolylmaleimide-1 
(Bim-1) 
Cayman Chemical 50mM (DMSO) 
LY294002 (Cell Signaling) Cell Signaling 50mM (DMSO) 
U0126 Cell Signaling 50mM (DMSO) 
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PD98059 Cell Signaling 10mM (DMSO) 
CdCl2 Sigma Aldrich 100mM dH2O 
 
All drugs were diluted to final concentrations in ACSF on the day of 
experimentation. Final treatment solutions were adjusted to contain 1% DMSO. 
Additionally, all drug treatments began immediately after tissue dissection. Exposure to a 
drug and BDNF were begun simultaneously. Total exposure time was 5 hours. A vehicle 
control (ACSF + 1% DMSO) was included with each drug treatment. 
 
Tissue preparation and immunohistochemistry 
Following dissection, tissue was immersed in 4% paraformaldehyde at 4°C 
overnight, rinsed in phosphate-buffered saline (PBS) and equilibrated in 30% sucrose in 
PBS at 4°C overnight. Tissue was frozen in Optimal Cutting Temperature media (OCT) 
(Tissue Tek) and cryo-sectioned into 20µm transverse sections. Sections were incubated 
in normal goat serum (NGS) for 1 hour, rinsed with PBS and incubated in primary 
antibody at 4°C overnight. Secondary antibodies were applied for 1 hour at room 
temperature. Tissues were imaged with a fluorescent microscope or an Andor CSU W1 
spinning disk confocal microscope. No primary controls were done with each experiment 
to insure there was no non-specific binding of the secondary antibody. 
 
 Afferent labeling and multiphoton imaging 
 120 hour old embryos (E5; HH st.25) were inspected to determine embryonic 
stage. Embryos were removed from their egg sac, decapitated, eviscerated and pinned 
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into a dissection dish dorsal side up. A capillary pipet containing 1,1’dioctadecyl-
3,3,3’3’-tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes) was 
transiently placed into thoracic level 3 or 4 (T3 or T4) DRG on one or both sides of the 
spinal cord. DiI was delivered to the tissue via nitrogen gas pressure supplied by a 
Picospritzer III (1ms pulse, 40pA). Manipulation of the capillary pipet was controlled by 
a micromanipulator. This allowed for direct injection of DiI into the tissue and labeling of 
DRG.  
 Following DRG labeling, the tissue was rinsed in ACSF and transferred to a 0.4 
µm Millicell (Millipore) in a 35mm sterile culture dish to allow a controlled delivery of 
either drug solution or control solution (ACSF+1% DMSO). Tissue was incubated for 5 
hours at 37°C in 5% CO2 incubator and then fixed in 4% PF for >24 hours. Tissue was 
then washed in PBS and imaged with a BioRad Multiphoton Microscope. Axon length 
measurements were made with Volocity software. The z series images were flattened 
using ImageJ. 
 
Statistical analysis  
All statistical analysis was completed using PRISM scientific graphing software 
from Graphpad (GraphPad Software, San Diego). A one-way analysis of variance 
(ANOVA) was used to compare mean axon length of ≥3 treatment groups. Tukey’s Post-
hoc-test (two tailed) was used to compare mean axon length of 2 treatment groups. 






Inhibition of TrkB signaling attenuates DRG axon extension 
At HH st.25 DRG axons form the longitudinal pathway by extending rostrally and 
caudally along the longitudinal axis of the spinal cord. Previous studies indicate BDNF, 
the endogenous ligand for TrkB, increases neurite outgrowth in dissociated chicken DRG 
in vitro (Lindsay et al., 1985) . A similar enhancement in DRG axon extension has been 
observed in response to BDNF in the developing longitudinal pathway (McNamara et al., 
2015). Therefore, we asked whether activation of TrkB by its endogenous ligand, BDNF, 
was involved in the regulation of DRG axon extension in the longitudinal pathway.  
Using immunohistochemistry, we determined TrkB was present within DRG cell 
bodies, axons and dorsal root entry zone (DREZ) [Figure 3-1A, B]. We then asked 
whether inhibition of TrkB affected DRG axon extension in the longitudinal pathway. 
Exposure to the kinase inhibitor K252a [200nM] significantly attenuated DRG axon 
extension. However, K252a is known to inhibit tyrosine phosphorylation and kinase 
activity on all Trk receptors (Hashimoto, 1988).  Therefore, to specifically inhibit TrkB, 
preparations were treated with rabbit α TrkB IgG function blocking antibody. Exposure 
to this blocking antibody attenuated DRG axon extension. DRG axon extension was not 
affected by treatment with vehicle control solution or rabbit IgG [Figure 3-1C]. 
As blocking TrkB attenuated axon extension, we then focused on the 
contributions of TrkB activated intracellular signaling pathways: PLC- γ, MAPK and 
PI3K. We investigated whether these signaling pathways contributed to the endogenous 
extension of DRG axons. In the first set of experiments, we found inhibition of PLC- γ 
signaling attenuated DRG axon extension. Specifically, we found exposure to the PLC- γ 
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inhibitor U73122 [1µM, 3µM] significantly attenuated DRG axon extension [Figure 3-
2A].  
Next, we investigated the contributions of the MAPK signaling pathway to DRG 
axon extension. We tested the contribution of this pathway with the inhibitors U0126 [10 
μM], a selective inhibitor of MEK1 and MEK2 and PD8059 [2μM], an inhibitor of 
MEK1 activation. Neither inhibitor had an effect on DRG axon extension [Figure 3-2B]. 
We then investigated the potential contribution of the PI3K signaling pathway on DRG 
axon extension. Exposure to the PI3K inhibitor LY294002 at 10μM had no effect on 
DRG axon extension whereas at 20μM, LY294002 significantly attenuated DRG axon 
extension [Figure 3-2C]. 
 
Inhibition of TrkB stimulated PLC-γ signaling attenuates DRG axon extension 
 BDNF, the high affinity ligand for TrkB has been shown to promote DRG axon 
extension in the developing longitudinal pathway (McNamara et al., 2015). We next 
asked whether the presence of a PLC- γ inhibitor would attenuate BDNF stimulated DRG 
axon extension when applied along with the neurotrophic factor BDNF. We found DRG 
axon extension was attenuated when exposed to both U73122 [3μM] and BDNF 
[100ng/ml] [Figure 3-3A].  
 As activation of TrkB is known to elicit the PI3K and MAPK signaling pathways, 
we then asked whether exposure to LY294002, an inhibitor of PI3K signaling, or U0126, 
an inhibitor of MAPK signaling, would affect BDNF stimulated axon extension when the 
inhibitors were added along with BDNF. Following exposure to either inhibitor along 
with BDNF (U0126 [100μM] + BDNF [100ng/ml] or LY294002 [20μM] + BDNF 
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[100ng/ml]) DRG axon extension was comparable to that produced by BDNF [100ng/ml] 
alone [Figure 3-3B, C].  
We used immunohistochemistry to confirm that U0126 inhibited MAPK signaling 
in the chicken preparation. Embryos were exposed to U0126 [100μM] alone or during 
application of BDNF [100ng/ml] and stained for phosphorylated ERK (pERK). Less 
pERK immunoreactivity was evident in embryos exposed to U0126 + BDNF than in 
embryos exposed to vehicle control solution or BDNF alone [Figure 3-4A-C]. Thus, 
U0126 blunted pERK levels with and without BDNF stimulation in this preparation. 
 
IP3 induced Ca2+ release, but not DAG generation contributes to the BDNF 
stimulation of DRG axon extension 
BDNF activation of TrkB can elicit PLC-γ signaling, the generation of IP3 and 
release of Ca2+ from IP3 sensitive intracellular Ca
2+ stores (Yoshii and Constantine-Paton, 
2010). As inhibition of PLC-γ attenuated DRG axon extension, we tested whether a 
BDNF induced release of Ca2+ from IP3 sensitive intracellular Ca
2+ stores was a factor 
stimulating DRG axon extension. To determine this, embryos were treated with 
Xestospongin-C (Xe-C), an allosteric IP3R inhibitor (Gafni et al., 1997). Xe-C [0.5µM, 
1µM] treatment significantly attenuated DRG axon extension [Figure 3-5A]. This 
inhibition by Xe-C implicated a rise in intracellular Ca2+ as a mechanism stimulating 
axon extension. To test this possibility further, we exposed preparations to the cell 
permeable Ca2+ chelator BAPTA-AM [5mM]. Exposure to BAPTA-AM significantly 
attenuated DRG axon extension [Figure 3-6B], providing additional support for the 
hypothesis that a rise in intracellular Ca2+ is a factor regulating axon extension.  
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We then investigated the effects of simultaneous exposure to Xe-C and BDNF on 
DRG axon extension. Co-treatment with Xe-C caused a significant attenuation of BDNF 
stimulated DRG axon extension. However, axon length was not different from that noted 
for embryos exposed to vehicle control solutions [Figure 3-6A].  
As activation of PLC-γ also leads to activation of the DAG/ PKC signaling 
cascade we tested whether activation of DAG signaling was also a factor, which 
contributed to DRG axon extension. Exposure to the DAG analogue OAG [10 µM] or the 
PKC inhibitor Bim1 [50 µM or 100 µM] had no effect on DRG axon extension [Figure 3-
5B], indicating that DAG/PKC signaling did not contribute to axon extension. 
 
Inhibition of Ca2+ influx through voltage gated Ca2+ channels (VGCC) attenuated 
afferent extension, but is not required for BDNF stimulation of afferent extension.  
Embryonic chicken DRG are electrically active cells with a diverse expression 
profile of VGCCs (Nowycky et al., 1985). As VGCCs are known to be present at this 
stage of development, we tested whether an elevation of intracellular Ca2+ due to Ca2+ 
influx through VGCCs also stimulates DRG axon extension. Exposure to CdCl2 
[100µM], an inhibitor of VGCCs attenuated DRG axon extension [Figure 3-7A]. 
Given the observation that exposure to CdCl2 suppressed DRG afferent extension 
in naïve preparations, we investigated whether the addition of CdCl2 along with BDNF 
affected the BDNF stimulation of axon extension. BDNF still enhanced axon extension 
during co-treatment with CdCl2 [100µM] and BDNF [100ng/ml]. Further, with co-
treatment, the magnitude of the trophic factor enhancement was comparable to that seen 





 Extension of DRG axons in the developing longitudinal pathway allows for 
communication between multiple spinal segments, a process essential for the 
coordination of reflexes. The molecular mechanisms regulating this growth pattern are 
largely uncharacterized. Our findings provide evidence for an endogenous mechanism 
that regulates DRG axon extension within the developing longitudinal pathway. Here, we 
show endogenous activation of the PLC-γ signaling pathway by stimulation of TrkB with 
BDNF regulates DRG axon extension within the developing longitudinal pathway. 
 Precedent for this study derives from the following observations. First, TrkB 
mRNA and protein have been detected in chicken DRG at a time when DRG axons are 
extending within the longitudinal pathway (Rifkin et al., 2000, Straub et al., 2007). 
Second, stimulation of DRG neurons with BDNF enhances DRG axon extension in the 
developing longitudinal pathway (McNamara et al., 2015). In line with these findings we 
found TrkB protein expression in chicken DRG and DREZ at HH st.25, a time when 
DRG axons are extending within the longitudinal pathway (Coutinho-Budd et al., 2008). 
The coincident expression of TrkB with the developmental time point at which DRG 
axons are extending within the longitudinal pathway prompted us to explore a potential 
role for TrkB in DRG axon extension. We found attenuated DRG axon length in response 
to TrkB inhibition and enhanced axon length in response to BDNF stimulation. These 
findings suggest TrkB activation with BDNF contributes to the regulation of axon 
extension within the longitudinal pathway. 
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As TrkB has the capacity to regulate DRG axon extension in the longitudinal 
pathway, we next sought to understand which of the endogenous intracellular signaling 
pathways utilized by TrkB affect DRG axon extension within the longitudinal pathway. 
We hypothesized endogenous PLC-γ signaling regulates DRG axon extension within the 
longitudinal pathway. Precedent for this hypothesis derives from in vitro investigations 
showing pharmacological stimulation of PLC-γ and IP3Rs enhances neurite outgrowth in 
model cell lines (Itoh et al., 2011). In line with these findings, we show inhibition of 
PLC-γ signaling attenuates DRG axon extension in the longitudinal pathway.  
To further test this hypothesis we then asked if either the inhibition of MAPK or 
PI3K signaling pathways had an effect on DRG axon extension. We found treatment with 
MAPK signaling inhibitor, U0126 had no effect on DRG axon extension. In contrast, 
treatment with the PI3K inhibitor LY294002 did blunt axon extension. Previous 
investigations of sensory neurite outgrowth show PI3K signaling is involved in sensory 
neurite outgrowth (Ernfors et al., 1995). Thus, consistent with earlier studies, our findings 
suggest PI3K signaling also contributes to afferent extension in the chicken embryo in 
situ.  
To further examine the effects of endogenous PLC-γ signaling on DRG axon 
extension, we focused on the effects of PLC- γ to activate 1) Ca2+ influx from IP3 
sensitive intracellular stores and 2) activation of DAG/PKC signaling. Our results suggest 
IP3 induced release of Ca
2+ from intracellular stores contributes to the regulation of DRG 
axon extension, whereas activation of the DAG/PKC signaling cascade does not. Prior 
studies indicate that PKC signaling can have opposite or similar effects. For instance, 
activation of PKC signaling has been shown to enhance neurite outgrowth in chicken 
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ciliary ganglia, whereas it has been observed to inhibit neurite outgrowth in NG108-15 
cells (Sprague, 1958, Davies et al., 1986, Mu et al., 1993). The different responses 
suggest that the contribution of DAG/PKC signaling is cell type and substrate dependent. 
Our results suggest activation of the DAG/PKC signaling cascade is not required for 
afferent extension in the developing longitudinal pathway in the chicken embryo in situ. 
With evidence that PLC-γ signaling contributes to the endogenous regulation of 
DRG axon extension, we then asked whether BDNF activation of TrkB regulates DRG 
axon extension through PLC-γ signaling. DRG axons did not respond to TrkB stimulation 
following inhibition of PLC-γ signaling. These findings suggest activation of TrkB and 
subsequent PLC-γ signaling contribute to DRG axon extension in the longitudinal 
pathway. 
 We then asked whether MAPK and/or PI3K signaling pathways had an effect on 
DRG axon extension in response to TrkB stimulation. Enhanced extension was observed 
in response to TrkB stimulation following inhibition of MAPK and/or PI3K inhibition. 
These findings suggest that while PI3K signaling contributes to the endogenous 
regulation of DRG axon extension in the longitudinal pathway, this signaling is not 
entirely dependent on TrkB activation. These findings are not surprising, as PI3K 
signaling occurs in response to not only tyrosine kinase receptors, but by Ras, G- protein 
coupled receptors- Gβγ subunits and recently by neuronal tyrosine phosphorylated 
Adaptor for PI3K (NYAP) (Chu-Wang and Oppenheim, 1978, Mack and Eickholt, 2011). 
An alternative explanation for these findings could be that LY294002 inhibits PI3K 
signaling at a slower rate than BDNF activates TrkB to promote DRG axon extension. 
These results would suggest that while PI3K signaling is important for regulation of DRG 
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axon extension, and that inhibition of this signaling can be overcome by addition of 
exogenous BDNF. This study required all embryos to be incubated for approximately 5 
hours. This was to ensure DRG axons were given the same opportunity to extend within 
the longitudinal pathway. Thus, studies to explore the timing of the effects of different 
drug treatments were not feasible under the experimental paradigm. 
 We also examined the role of TrkB activated release of Ca2+ from IP3 sensitive 
intracellular stores on DRG axon extension. We hypothesized that inhibition of IP3 
induced release of Ca2+ from intracellular stores during TrkB stimulation would attenuate 
DRG axon extension. We observed inhibition of IP3 induced release of Ca
2+ stores 
blunted the enhanced extension mediated by TrkB stimulation. These results are 
consistent with previous observations that neurite extension in chicken embryos during 
early development (≤E10) requires elevation of intracellular Ca2+ via release of IP3 
sensitive Ca2+ stores (Arie et al., 2009). While TrkB activation in the presence of 
inhibition of Ca2+ release from IP3 sensitive stores attenuated DRG axon extension 
relative to TrkB stimulation alone, there was no significant difference in DRG axon 
extension relative to treatment with vehicle control. These results suggest TrkB activation 
may be operating via an additional mechanism to enhance intracellular Ca2+ levels and 
promote DRG axon extension. To investigate other mechanisms of Ca2+ entry into the 
intracellular environment, we focused on VGCCs. Previous investigations demonstrate 
that neuronal depolarization opens VGCCs, allowing for Ca2+ influx and elevation of 
intracellular Ca2+. Neuronal depolarization and subsequent influx of Ca2+ has been shown 
to increase the expression of TrkB in cultured cortical neurons (Nowycky et al., 1985, 
Kingsbury et al., 2003). Our findings that inhibition of VGCCs attenuates afferent 
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extension are consistent with previous investigations that VGCC activity is required for 
endogenous regulation of afferent extension (Gomez et al., 1995).  
As blocking VGCCs attenuated axon extension in the absence of exogenous 
BDNF, we next asked whether co-treatment with BDNF and CdCl2 affected DRG axon 
extension.  
The observation that TrkB stimulation still enhanced axon growth when VGCC 
were blocked, suggests release of IP3 sensitive intracellular stores may be the primary 
mechanism for the rise in intracellular Ca2+ that contributes to the regulation of afferent 
extension in the longitudinal pathway. These findings were consistent with investigations 
by Arie et al. (2009) showing neurite outgrowth depends upon IP3 sensitive intracellular 
Ca2+ store release during early development and ryanodine receptors at later stages in 
development (Arie et al., 2009).  
Collectively, these findings provide evidence for an endogenous mechanism that 
regulates DRG axon extension within the developing longitudinal pathway. Importantly, 
this mechanism can be manipulated to enhance or attenuate axon extension in developing 
tissue. Ultimately, an understanding of the mechanism driving axon extension is 
important not only for our understanding of how axons grow during development, but 
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Figure 3-1. Inhibition by Trk inhibitor K252a and TrkB function blocking antibody 
attenuates DRG axon extension. A. Epi-fluorescent images of transverse sections 
(20µm) of spinal cord (SC) and DRG TrkB immunoreactivity in DRG, DREZ and SC. B. 
No primary control. Scale bar = 100µm. C. Exposure to K252a [200nM] (n= 9) to inhibit 
TrkB attenuated DRG axon extension relative to VC (n=8). Inhibition of TrkB with a 
rabbit αTrkB IgG function blocking antibody [11ng/ml] (n=8) attenuated axon extension 













Figure 3-2. Inhibition of PLC-γ and PI3K but not MAPK signaling, attenuated DRG 
axon extension. A. U73122 attenuated DRG axon extension at 1µM [U73122 (n=19), 
VC (n=10)] and 3µM [U73122 (n=4), VC (n=5)], but not at 0.5µM [U73122 (n=4), VC 
(n=5)]. B. Exposure to 2µM PD8059 (n=6) had no effect on axon extension relative to 
VC (n= 5). Exposure to 10µM U0126 (n=8) had no effect on DRG axon extension 
relative to VC (n=5). C. Exposure to 10µM LY294002 had no effect on DRG axon 
extension (n=9) whereas 20µM LY294002 (n=9) significantly attenuated DRG axon 




















Figure 3-3. Inhibition of TrkB stimulated PLC-γ but not MAPK or PI3K signaling 
attenuates DRG axon extension. A. U73122 [3µM] (n=4) attenuates axon extension 
induced by BDNF [100ng/ml] (n=7). BDNF [100ng/ml] (n=6) enhances axon extension 
relative to VC treatment (n=7). B. U0126 [100µM] (n=6) had no effect on axon extension 
relative to VC (n=7). Exposure to either BDNF [100ng/ml] or BDNF [100ng/ml] +U0126 
[100µM] (n=6) enhanced axon extension. C. LY294002 [20µM] (n=5) attenuates DRG 
axon extension induced by BDNF [100ng/ml] (n=5). Exposure to BDNF ([100ng/ml] 



















Figure 3-4. Exposure to U0126 [100µM] inhibits phosphorylation of ERK. (A-E) 
Immunoreactivity for pERK following a 5 hour exposure with one of the following 
conditions A. VC (ACSF+1% DMSO) exposure. B. BDNF [100ng/ml] exposure C. 
Simultaneous exposure of BDNF [100ng/ml] +U0126 [100µM] exposure. Scale bar = 
























Figure 3-5. Role of PLC-γ related signaling events in DRG axon extension. A. 
Inhibition of Ca2+ release from IP3 sensitive intracellular Ca
2+ stores attenuates DRG 
axon extension. Exposure to Xe-C at 0.1µM (n=6) had no effect on axon extension 
compared to VC (n=4), whereas, exposure to Xe-C at 0.5µM (n=8) and [1µM] (n=10) 
attenuated axon extension compared to VC exposure (n=13). B. Exposure to a DAG 
analogue or a PKC inhibitor did not attenuate DRG axon extension. Treatment with OAG 
[10µM] (n=6) had no effect on DRG axon extension as compared to VC exposure (n=5). 
Exposure to Bim1 at 50 µM (n=6) or 100 µM (n=9) had no effect on DRG axon 



























Figure 3-6. Exposure to Xe-C or BAPTA-AM blunted axon extension in the 
absences and presence of added BDNF. A. Exposure to Xe-C [1µM, (n=6)] suppressed 
axon extension. The inhibition of Xe-C was not reversed when Xe-C and BDNF were 
applied together [Xe-C 1 µM, BDNF 100ng/ml (n=5)]. B. Exposure to the cell permeable 
Ca2+ chelating agent BAPTA-AM attenuated DRG axon extension [BAPTA-AM 5mM 
(n=6), VC (n=8)]. The addition of BAPTA-AM along with BDNF did not reverse the 
effect of the treatment with the cell permeable Ca2+ chelator [BAPTA-AM 5mM and 
BDNF 100ng/ml (n=5), VC (n=8), BDNF 100ng/ml (n=5)]. 
























Figure 3-7. CdCl2 treatment attenuated axon extension when applied alone, but did 
not blunt BDNF stimulated axon extension. A. Exposure to CdCl2 [100 µM] (n=4) 
attenuated DRG axon extension compared to VC (n=6). B. When BDNF [100ng/ml] and 
CdCl2 [100µM] were applied together (n=6), axon extension was similar to BDNF alone 


























Summary, discussion, interpretations and future directions 
 
Summary of findings 
 The purpose of this dissertation was to investigate the endogenous regulation of 
dorsal root ganglia (DRG) primary sensory afferent extension within the developing 
longitudinal pathway of the spinal cord, an important growth pattern for the 
intersegmental coordination underlying reflex formation. In this work, I have 
manipulated afferent extension within the longitudinal pathway by pharmacologically 
manipulating BDNF-TrkB signaling. Using an in situ preparation, I found BDNF 
enhances afferent extension whereas disrupting BDNF signaling attenuates afferent 
extension in the longitudinal pathway in situ. BDNF binds with high affinity to TrkB, a 
tyrosine kinase receptor known to promote growth and survival in DRG neurons in vitro. 
Disruption of TrkB or TrkB dependent PLC-γ signaling attenuates afferent extension in 
the longitudinal pathway. In contrast, blocking TrkB dependent PI3K or MAPK signaling 
had no effect on afferent extension within the longitudinal pathway. Thus, I propose that 
DRG axon extension in vivo is regulated by release of Ca2+ from IP3 sensitive stores 
following BDNF activation of TrkB and initiation of PLC-γ signaling.  
 As BDNF was shown to enhance afferent extension in the longitudinal pathway, I 
then sought to investigate the effects of fingolimod-p, an S1P1R agonist known to 
enhance BDNF mRNA and protein production in mouse embryonic cortical neurons 
(Deogracias et al., 2012, Doi et al., 2012). I found fingolimod-p enhances BDNF mRNA 
production and enhances afferent extension via a BDNF related mechanism.  Thus, I 
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propose S1P1R activation by fingolimod-p enhances DRG axon extension in the 
longitudinal pathway through a BDNF related mechanism. A summary of the results in 
this dissertation is shown table 4-1. Other experiments from our laboratory are 
summarized in table 4-2 and will be integrated into this discussion. 
 
Discussion and interpretation 
 
 The molecular mechanisms that regulate DRG afferent extension in the 
longitudinal pathway in situ are poorly understood. Previous studies have investigated the 
molecular events leading up to longitudinal extension. Following coalescence of DRG 
from migrating neural crest cells, afferents extend towards the developing spinal cord. 
The growth of these afferents towards the dorsal root entry zone (DREZ) is controlled by 
repulsive cues mediated by netrins, a family of diffusible factors that act as either 
attractive or repulsive cues depending upon the receptor they interact with. Netrin 
expression can be found in the floor plate and an expression gradient with high netrin 
expression in the ventral spinal cord and low netrin expression in the dorsal spinal cord 
can be observed throughout early embryonic chicken development. At E3 HH st.22, 
netrins act on the Unc5c receptor to mediate chemorepulsive actions away from the floor 
plate and ventral spinal cord. Previous investigations of netrin signaling in the chicken 
embryo find that siRNA knockdown of netrin-1 results in aberrant growth towards the 
floor plate and notochord, further supporting netrins as a repulsive factor that controls 
afferent pathfinding in the developing chicken embryo (Masuda et al., 2008). 
 How netrins interact with BDNF-TrkB signaling in developing afferents 
extending within the longitudinal pathway is not entirely understood. One investigation 
using Xenopus spinal neurons found netrins and BDNF operate together to promote 
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chemotaxis. In this study, a netrin gradient was found to control the sensitivity of the 
growth cone to BDNF by modulating the number of TrkB receptors in the growth cone 
(Ming et al., 2002). It is possible that afferent extension within the longitudinal pathway 
is controlled by both the chemoattractive forces of BDNF-TrkB signaling and the 
chemorepulsive forces of netrins. Previous investigations in E12.5 mouse (equivalent to 
E5 in chicken) find netrin release from the dorsal spinal cord. Netrins then activate Unc 
receptors on DRG axons resulting in repulsion away from the spinal cord grey matter and 
thus keeping them within the longitudinal pathway (Masuda et al., 2009). It is likely that 
netrins are also secreted from E5 st. 25 chicken dorsal spinal cord in situ, that they 
repulse afferents away from the dorsal spinal grey matter and maintain afferent growth 
within the longitudinal pathway.     
Once afferents penetrate the DREZ, their rostral to caudal bifurcation is controlled 
by cGMP signaling. Exposure to a cGMP analogue, Br-cGMP or YC-1, a soluble 
guanylyl cyclase (sGC) activator, increases the number of branch points of E14 rat DRG 
in vitro. In contrast, an inhibitor of protein kinase cGMP-1 (PrkG1), a downstream 
effector of cGMP signaling, prevents axon bifurcation (Zhao et al., 2009). Further studies 
of DRG axon bifurcation suggest interactions between cardiac naturitic protein (CNP) 
and its receptor natriuretic peptide receptor 2 (NPR2) regulate afferent bifurcation 
through cGMP signaling. Similar to experiments in which PrkG1 was blocked, CNP 
knockouts produced afferents that fail to bifurcate but turn to extend in only one 




BDNF is known to enhance levels of cAMP and support axon pathfinding and 
turning. Whether activation of TrkB with BDNF or the intracellular signaling pathways 
elicited by TrkB activation are important for axon bifurcation is unknown. One possible 
scenario is that cAMP is elevated during axon bifurcation and attenuated when afferents 
begin to extend within the longitudinal pathway. While this has not been directly tested, 
cAMP has been shown to initiate a turning response in the growth cone of Xenopus 
spinal neurons in vitro (Lohof et al., 1992).  
S1P1Rs are G protein coupled receptors activated by sphingosine-1 phosphate, a 
sphingolipid derivative of Sphingomyelin (Bigaud et al., 2014). Fingolimod-p is a 
structural analogue of S1P and an agonist for S1PRs. Activation of S1PRs allows for the 
elicitation of various intracellular signaling pathways that affect cAMP signaling. 
Specifically, activation of the S1P1R inhibits adenylate cyclase and subsequently 
decreases levels of cAMP (Means and Brown, 2009).  
Previous studies of afferent extension within the longitudinal pathway find 
extension can be manipulated pharmacologically (Coutinho-Budd et al., 2008) [Table 4-
2]. In that study, using an intact chicken embryo in ovo preparation (E6), exposure to 
forskolin, an adenylate cyclase activator, attenuates afferent extension within the 
developing longitudinal pathway. In contrast, exposure to H89, a PKA inhibitor, 
enhances afferent extension (Coutinho-Budd et al., 2008). These findings are contrary to 
studies done in adult neurons where elevation of cAMP enhances neuronal 
responsiveness to growth factors such as BDNF, and promotes regeneration of 
axotomized neurites (Spencer and Filbin, 2004). In vivo in adult animals, elevation of 
cAMP by addition of cell permeable cAMP analogues enhances regeneration of DRG 
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axons whereas inhibition of PKA prevents regeneration in lesioned spinal axons in the 
dorsal columns of 5 week old rats (Qiu et al., 2002). In E5 HH st.25 chicken embryo 
preparation, and consistent with in ovo studies by Coutinho-Budd et al., (2008), blocking 
cAMP signaling enhances afferent extension and activating adenylate cyclase attenuates 
afferent extension (preliminary studies, data not shown).  
There are many potential explanations for these findings. One possibility is that in 
vitro investigations of the involvement of cAMP in axon growth do not take into account 
the possibility that additional signaling mechanisms and/or substrates may influence 
cAMP signaling within the intact embryo. For instance, the intact embryonic chicken 
spinal cord contains sonic hedgehog (Shh) signaling, an important developmental 
signaling event required for axon guidance in longitudinal spinal cord tracts. Shh acts 
through the receptors Patched and Smoothened to attenuate levels of cAMP and reduce 
PKA signaling (Bovolenta and Sanchez-Arrones, 2012). Thus, it is possible that in situ 
Shh signaling is an important mechanism for blocking cAMP signaling so that afferents 
may extend within the longitudinal pathway.  This effect would not be seen in dissociated 
DRG neurons grown in vitro, and therefore may account for the discrepancy in the results 
obtained from in vitro and in situ preparations.   
Another potential explanation for these findings is that S1P1R may be transported 
to the cell membrane during the developmental time period when afferents are extending 
within the longitudinal pathway. Activation of S1P1Rs would inhibit adenylate cyclase 
and subsequently attenuate cAMP levels in the developing axons. A model proposed by 
Forbes et al., (2012) using rat sympathetic neurons in vitro shows that when levels of 
baseline Ca2+ are high, reducing cAMP levels promotes growth cone attraction (Forbes et 
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al., 2012). Previous investigations suggest elevation of intracellular Ca2+ is essential for 
axon extension (Connor, 1986a, Arie et al., 2009a)  Further, we show chelation of 
intracellular Ca2+ attenuates afferent extension within the longitudinal pathway. Thus, it 
is likely that high intracellular Ca2+ levels and low cAMP levels promote DRG afferent 
extension within the longitudinal pathway.    
Another potential contributing factor to the effect of cAMP on afferent extension 
is the substrate upon which afferents are grown. Differences in substrate composition 
affect afferent rate of extension in vitro. Koch et al., (2012) found changes in substrate 
tension affect DRG neurite extension such that as tension increases neurite extension 
increased (Koch et al., 2012). Additionally, E7 chicken DRG express lower levels of 
cAMP when plated on a substratum composed of low laminin concentrations, whereas 
high levels of cAMP are seen in response to being plated on high laminin substrates 
(Lemons and Condic, 2006). Additionally, integrin activation significantly decreases 
intracellular cAMP on both low and high laminin (Lemons and Condic, 2006). The 
substrate upon which DRG afferents grow within the longitudinal pathway is 
uncharacterized. Thus, low levels of laminin within the endogenous substrate could be 
one possible explanation as to why inhibition of the downstream effector of cAMP 
enhances afferent extension in situ. 
Another potential explanation for the differential effects of cAMP signaling in 
vitro and in situ may be the result of the difference between intact and regenerating 
systems. In embryonic systems in which neurons have been dissociated, regenerative 
capacity can be prevented by blocking cAMP signaling with PKA inhibitors or cAMP 
antagonists (Spencer and Filbin, 2004). Another study found dissociated, embryonic 
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DRG and retinal ganglia axon extension was enhanced following inhibition of PKG or 
addition of cAMP analogue, db-cAMP (Cai et al., 2001). While there are many 
similarities between developmental growth and regenerative growth, such as the 
requirement for the advancement of the growth cone and the assembly of the 
cytoskeleton, there are distinct differences that make studies using dissociated neurons 
distinctly different from intact, developing neurons (Zhou and Snider, 2006). One 
important difference is the requirement of the growth cone of the regenerating axon to 
travel through variable terrain where it may encounter extracellular factors that affect its 
ability to assemble the axon. This is distinctly different from developing neurons that are 
known to be guided by repulsive and attractive cues that guide them along specific 
pathways to their targets (Zhou and Snider, 2006).  
Additional studies on extension of primary afferents in the longitudinal pathway 
have found pharmacological manipulation of the neuronal cytoskeleton affects afferent 
extension [Table 4-2]. For example, exposure of E5 (HH st.25) chicken in situ 
preparations to Nocodzol, a pharmacological agent known to interfere with 
polymerization of microtubules, attenuates afferent extension, whereas exposure to 
Jasplakinolide, an actin polymerizing and stabilizing agent, enhances afferent extension 
in the longitudinal pathway (Mariani et al., 2011). BDNF has been shown to induce 
translation of β-actin in the axon and growth cone of rat cortical neurons in vitro (Sasaki 
et al., 2010). Thus, it is likely that BDNF also regulates actin polymerization of 
longitudinally extending afferents in the developing chicken embryo. One potential 
mechanism for the regulation of actin polymerization by BDNF could be through 
activation of the TrkB receptor and release of Ca2+ from IP3 sensitive stores via elicitation 
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of the PLC-γ signaling pathway. Release of Ca2+ from these stores may activate Ca2+ 
dependent kinases such as Ca2+ -calmodulin-dependent kinases (CAMK), a family of 
signaling molecules known to be important for cytoskeletal remodeling, including actin 
polymerization and axon elongation in rat hippocampal and cerebellar neurons through 
regulation of growth cone motility (Wayman et al., 2004, Rosenberg and Spitzer, 2011).  
   Given a potential model for afferent extension that requires activation of TrkB 
with BDNF and release of Ca2+ from IP3 sensitive stores via activation of PLC-γ 
signaling, another critical question is: what is the location of BDNF in this preparation? 
In vivo, BDNF can be secreted in an autocrine/paracrine manner or from a distal target to 
promote target innervation of sensory neurons. In the chicken embryo, afferents growing 
within the longitudinal pathway have multiple targets in the spinal cord and developing 
brain stem. At E5 (HH st.25), afferents have not made contact with any of their potential 
targets. Further, individual afferents within the longitudinal pathway have targets in both 
the rostral and caudal direction. It is possible that there are two sources of BDNF that 
guide afferents in the rostral or caudal direction, although it is unclear how a gradient 
could set up in opposing directions along multiple segments that would result in rostal 
and caudal extension of these axons. A more likely scenario is that BDNF signals in an 
autocrine/paracrine manner. This is supported by the fact that BDNF mRNA and protein 
are found in DRG neurons during chicken development. 
It is also possible that BDNF and TrkB are locally translated within the growth 
cone. To explore this possibility in an E5 chicken in situ preparation, afferents could be 
labeled with DiI and incubated for 15 minutes to allow for DiI to label the growing 
afferent. DRG cell bodies could then be removed prior to the 5 hour incubation growth 
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assay. Persistence of afferent extension within the longitudinal pathway would be a 
strong indication that local protein synthesis is required for afferent extension. To 
confirm local axon synthesis of BDNF is required for afferent extension, afferents could 
be labeled with DiI and incubated for 15 minutes to allow DiI to label the afferents. 
Afferents could then be disconnected from their cell bodies. The afferents, which remain 
within the preparation could be treated with fingolimod-p or fingolimod-p and αBDNF 
function blocking antibody. Enhanced afferents extension with fingolimod-p treatment 
and attenuated afferent extension with fingolimod-p and αBDNF function blocking 
treatment following removal of the DRG cell bodies would suggest S1P1Rs and TrkB 
receptors are not required in the cell body to regulate axon extension within the 
longitudinal pathway.  
 Another compelling question is: how does BDNF arrive at the growth cone? 
Various lines of evidence suggest axonally localized transcripts can be translated within 
the growth cone. Specifically, proteins known to be involved in axon elongation and 
responses to guidance cues have been shown to be translated locally within axon growth 
cones. In one study using severed axons from E14 rat DRG found NGF enhanced 
expression of Par3 protein, a regulator of cytoskeletal dynamics (Hengst et al., 2009). 
These data suggest translation of proteins involved in axon elongation occurs locally 
within the growth cone. To date, there is no evidence that BDNF is transcribed and 
translated in the developing growth cone. Rather, it is more likely that BDNF is 
transcribed and translated in the neuronal cell body, and anterogradely transported to the 
axon and growth cone, as is seen in the rat DRG, optic nerve, and hippocampus (Menna 
et al., 2003, Ng et al., 2007). Rate of anterograde transport for BDNF was determined in 
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E18 rat hippocampus to be 1.49µm s-1 (Lo et al., 2011). Thus, over the course of a five 
hour incubation, BDNF has the potential to be transported >26,000µm. As the average 
length of a vehicle control treated DRG afferent in an E5 HH st.25 chicken in situ 
preparation is between 80-100 µm from cell body to the DREZ and 550-600 µm from the 
location of bifurcation to the most distal end of the growth cone, it is likely that BDNF is 
anterogradely transported from the cell body to the DRG growth cone during the five 
hour incubation period utilized in this work. TrkB is also known to be anterogradely 
transported to the axonal growth cone. Huang et al., (2011) found both full length and 
truncated isoforms of TrkB are anterogradely transported in hippocampal axons to the 
axonal growth cone via interactions with kinesin-1 motor protein (Huang et al., 2011). 
Thus, it is likely that BDNF and TrkB are transcribed and translated in the neuronal cell 
body and transported to the distal axon and growth cone via anterograde transport 
mediated by kinesins. Once at the growth cone, BDNF may be secreted allowing it to act 
in an autocrine and paracrine manner on TrkB expressing neurons.  
 In addition to autocrine signaling, BDNF is likely to signal via a paracrine 
mechanism as well. Previous investigations show TrkB mRNA in 47% of DRG cell 
bodies in E5 chicken embryos (Rifkin et al., 2000). Additionally, Straub et al., (2007) 
show TrkB positive afferents within the DREZ at HH st.25. (Straub et al., 2007). 
However, the number of TrkB positive afferents within the longitudinal pathway has yet 
to be quantified at HH st. 25. Previous investigations and the immunohistochemistry for 
TrkB done in this dissertation suggest TrkB is expressed in many of the developing 
afferents within the longitudinal pathway. Further experiments using quantitative 
immunohistochemistry would need to be done to determine the percentage of afferents 
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within the longitudinal pathway that are TrkB positive. There are two possible outcomes 
for quantitative immunohistochemistry using an E5 HH st.25 chicken embryo in situ 
preparation. The first is that all afferents within the longitudinal pathway are TrkB 
positive. This would suggest that TrkB is required for growth within this pathway. This is 
a possibility as the afferents growing within this anatomical pathway will become the 
dorsal columns, a longitudinal pathway associated with fine touch, two point 
discrimination and conscious proprioception from the skin and joints in the adult 
organism. At HH st. 25 afferents have not made contact with their peripheral sensory 
receptor (Guan et al., 2003). Thus, it may be that TrkB is regulating growth within the 
longitudinal pathway until the peripherally extending process makes contact with its 
receptor at HH st. 30 (Guan et al., 2003). Whether TrkB expression in centrally 
projecting DRG afferents is affected by peripheral projecting afferents’ contact with its 
receptors is unknown. Another possibility is that a subpopulation of afferents growing 
within the longitudinal pathway express TrkB. This is a possibility as some of the 
afferents within the longitudinal pathway are destined to different central targets. 
Additionally, these afferents may make connections with peripheral receptors that 
transduce different sensory modalities such as nociception, typically associated with 
TrkA expressing DRG or proprioception, typically associated with TrkC expressing 
DRG. These results would suggest afferent extension in the longitudinal pathway may be 
regulated by the activation of multiple Trk receptors. With both scenarios, BDNF likely 
signals via both autocrine and paracrine mechanisms. 
If BDNF is secreted from neurons and BDNF enhances afferent extension in the 
longitudinal pathway, then exposure to a pharmacological agent that enhances BDNF 
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mRNA and protein production should enhance afferent extension. Fingolimod-p is a 
sphingosine 1-phosphate analogue and an sphingosine-1 phosphate receptor (S1PR) 
agonist (Kong et al., 2014). While the effects of fingolimod-p as an S1PR agonist were 
originally studied in the immune system, as this drug was found to be a highly efficacious 
disease modifying treatment option for individuals suffering from relapsing-remitting 
forms of multiple sclerosis (RRMS), it has more recently been shown to enhance BDNF 
mRNA and protein production in mouse, embryonic, cortical neurons (Deogracias et al., 
2012, Doi et al., 2012). While BDNF mRNA transcription was increased in response to 
treatment with fingolimod-p in our preparation, we could not demonstrate BDNF protein 
secretion into the media of our preparation following treatment with fingolimod-p. 
Previous investigations observe enhanced BDNF production in response to treatment 
with fingolimod-p. The primary difference between these studies and ours is the location 
from which BDNF protein was assayed. Both Deogracias et al., 2012 and Doi et al., 2013 
assessed BDNF protein levels from cell lysates, whereas we attempted to quantify BDNF 
protein release into the media of our preparation (Deogracias et al., 2012, Doi et al., 
2012). Our rationale for assessing BDNF protein in the media was as follows. We were 
primarily interested in BDNF secretion from primary sensory afferents growing in the 
longitudinal pathway. As isolation of these afferents would have damaged the connection 
to the cell body, we chose to leave the spinal cord and DRG intact and assess release of 
BDNF into the media. The inability to detect BDNF secretion using this methodology 
may be the result of one or more of the following possibilities: 1) the amount of BDNF 
secreted from our preparation is below the limit of detection for the ELISA assay used 
(10-0.06ng/ml) (MyBiosource), 2) BDNF levels were unable to be detected due to the 
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inability of BDNF to diffuse through neuronal tissue and into the cell media, thus 
preventing its detection (Djordjevic and Driscoll, 2002) or 3) BDNF mRNA may be 
upregulated but BDNF protein may not. Exploration of these possibilities is needed to 
further understand how BDNF secretion may or may not occur in response to fingolimod-
p treatment. 
Once BDNF activates TrkB, the receptor trans-autophosphorylates on tyrosine 
residues resulting in the activation of three intracellular signaling pathways: the PLC-γ, 
PI3K and MAPK signaling pathways, each of which has been shown to mediate 
important effects on the developing nervous system. Activation of the PLC-γ signaling 
pathway allows for the release of Ca2+ from IP3 sensitive stores, an important process for 
elevating intracellular Ca2+ and neurite extension in early chicken DRG in vitro (Connor, 
1986b, Arie et al., 2009b). Arie et al., (2009) found chicken DRG neurons (≤ E10) 
expressed IP3Rs in their developing growth cones in vitro. Following E10, IP3R 
immunoreactivity is severely attenuated and blocking release of Ca2+ from IP3 sensitive 
stores had no effect on DRG neurite extension. This study suggests neurite outgrowth is 
differentially regulated throughout development by the means in which Ca2+ enters into 
the intracellular environment (Arie et al., 2009b). In this dissertation, release of Ca2+ 
from IP3 sensitive stores via activation of the TrkB activated PLC-γ signaling pathway 
was found to be important for afferent extension within the longitudinal pathway. 
However, unlike Arie et al., (2009), we found inhibition of voltage gated Ca2+ channels 
during early development attenuated afferent extension as well. It is possible that release 
of Ca2+ from IP3 sensitive stores and from the extracellular environment contribute to 
afferent extension within the longitudinal pathway. The difference seen in previous 
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studies and this work may be due to different model systems and/or that previous 
investigations used dissociated DRG neurons grown in vitro (Conner et al., 1997, Arie et 
al., 2009a). Damage to afferents resulting from the process of dissociation may alter the 
Ca2+ channels within the early developing DRG neuron thus altering the means by which 
Ca2+ enters into the developing neuron.   
How Ca2+ promotes afferent extension in the longitudinal pathway was not 
explored in this dissertation, however, there is compelling evidence to suggest differences 
in intracellular Ca2+ levels regulate axon growth. Singh and Miller in 2005 support this 
idea in experiments using neonatal mouse sympathetic neurons. In this work, membrane 
depolarization and enhanced intracellular Ca2+ signaling resulted in longer neurites in the 
presence of NGF. Additionally, these experiments found Ca2+ acts through Calcium-
calmodulin kinase II (CAMII), a kinase known to phosphorylate and activate additional 
members of the Ca2+ calmodulin family in the presence of Ca2+. Additional investigations 
of CaMK signaling on axon extension suggest that Ca2+ activated CamK signaling 
enhances afferent extension via interactions with the actin cytoskeleton. In these 
investigations CaMK1 localized to the axonal growth cone where it promotes actin 
polymerization and de-polymerization via interactions with substrates such as members 
of the Rho family of GTPases, which are known to regulate actin dynamics in filopodia 
and lamellipodia (Wayman et al., 2004). Additionally, CamKI phosphorylates myosin II, 
a mechanoenzyme known to be important for the regulation of E5 HH st.25 chicken DRG 
afferent extension within the longitudinal pathway (Wayman et al., 2004, Robinson et al., 
2015). Thus, it is likely that in E5 HH st. 25 chicken DRG elevation of intracellular Ca2+ 
due to PLC-γ dependent release of IP3 sensitive intracellular stores results in activation of 
139 
 
CaMKII which then phosphorylates CaMKI. CaMKI may then phosphorylate Rho 
GTPases to promote actin polymerization and organization of actin into F-actin. 
Additionally, CamKI may also phosphorylate and activate myosin II to promote axon 
extension within the developing longitudinal pathway.   
Activation of the PI3K and MAPK signaling pathways have been implicated in 
axon outgrowth as well. Activation of the PI3K signaling pathway leading to activation 
of AKT has been implicated in many aspects of neurite outgrowth such as: elongation, 
branching and survival. Markus et al., (2002) found treatment of dissociated, E13 mouse 
DRG with NGF increased terminal branching of sensory neurons by activation of PI3K-
AKT signaling and potentially through subsequent phosphorylation of AKT substrates 
known to interact with the actin cytoskeleton (Markus et al., 2002). While inhibition of 
PI3K in E5 HH st.25 chicken embryo DRG resulted in attenuation of afferent extension, 
addition of BDNF appeared to reverse the attenuating effect of exposure to the PI3K 
inhibitor. Thus, it is possible that BDNF acts on additional receptors to enhance extension 
in the longitudinal pathway. For instance, BDNF is known to activate P75NTR. While 
not explored in this study, P75NTR may become activated by BDNF and compensate for 
the loss of function due to inhibition of PI3K signaling.  Previous investigations using 
retinal ganglia neurons from embryonic chicken suggest P75NTR contributes to axon 
extension through deactivation of Rho-A, a cytoskeletal binding protein (Yamashita et 
al., 1999). Thus, it is likely that P75NTR is activated by BDNF and its signaling 
contributes to afferent extension in the longitudinal pathway in this preparation, 
potentially via interactions with the axon cytoskeleton. 
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The MAPK signaling pathway has also been shown to contribute to neurite 
outgrowth in embryonic sensory neurons. Markus et al., (2002) found inhibition of Raf-1 
or Ras prevents NGF induced axon growth in E13 mouse embryonic sensory neurons in 
vitro (Markus et al., 2002). Pharmacological inhibition of the MAPK signaling pathway 
with MEK inhibitors did not appear to have an effect on DRG afferent extension in E5 
HH st.25 chicken embryo with or without BDNF stimulation. One explanation for these 
findings is that endogenous MAPK signaling does not influence axon extension in this 
developmental time period. This may be possible if the downstream effects of MAPK 
signaling such as regulation of transcription, occurs prior to E5 HH st. 25. Another 
potential explanation for these findings is that MAPK signaling is required for afferent 
extension within the longitudinal pathway, and that blocking MAPK signaling in the five 
hour treatment window had no effect on transcription and/or translation of proteins, two 
events known to be regulated by MAPK signaling.   
 
Conclusions and Future directions 
In summary, the following model is proposed for the regulation of afferent 
extension in the longitudinal pathway. BDNF is anterogradely transported from the cell 
body to the axon growth cone where it is secreted, allowing it to act upon TrkB receptors 
in an autocrine and paracrine manner. Activation of TrkB with BDNF results in 
transautophosphorylation of the TrkB receptor on tyrosine residues resulting in the 
elicitation of intracellular signaling pathways: PLC-γ, PI3K and MAPK pathways. TrkB 
activation of the PLC-γ signaling pathway allows for release of Ca2+ from IP3 sensitive 
Ca2+ stores. This release of Ca2+ activates Ca2+ dependent kinases such as CAMKII and 
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Ca2+ dependent actin binding proteins known to interface with the axonal cytoskeleton 
and promote growth cone motility and remodeling. Additionally, release of IP3 sensitive 
Ca2+ stores may also induce a Ca2+ induced Ca2+ release thereby promoting opening 
ryanodine sensitive channels on the ER membrane resulting in additional elevation of 
intracellular Ca2+ and activation of Ca2+ dependent kinases and Ca2+ activated actin 
binding proteins [Figure 4-1]. Fingolimod-p, through activation of the S1P1R increases 
BDNF transcription and translation through activation of the MAPK signaling pathway. 
Activation of the MAPK signaling pathway through this means results in the 
phosphorylation of CREB, a protein known to regulate the transcription of BDNF. 
CREB-P then promotes BDNF transcription resulting in increased translation of BDNF 
protein. BDNF can then be anterogradely transported from the cell body to the growth 
cone where it is secreted so that it may act on TrkB and promote TrkB signaling [Figure 
4-1].  
Interestingly, inhibition of the MAPK signaling pathway does not affect afferent 
extension within the longitudinal pathway. It is possible that fingolimod-p activates 
MAPK signaling and enhances BDNF mRNA and protein production before U0126 and 
PD98059, the MAPK inhibitors used in this dissertation, effectively supresses MAPK 
signaling. Another possibility is that fingolimod-p may activate CREB through PLC 
dependent release of Ca2+ from IP3 sensitive stores and activation of CAMK signaling. 
CAMK signaling may then phosphorylate CREB and enhance BDNF transcription (Yoon 
et al., 2008).  Future investigations could look at the effect of blocking MAPK signaling 
in the presence of fingolimod-p.  
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One intriguing question that remains unanswered in these studies is: what is 
driving axons to grow within the longitudinal pathway? One possible answer to this 
question is a combination of repulsive and attractive guidance cues as well as the trophic 
factors. The preparation used in this study is an excellent model system for an 
investigation of how different signaling mechanisms interact to affect axon growth in a 
specific anatomical pathway. Future investigations could investigate the interactions of 
repulsive or attractive guidance factors such as netrins, semaphorins and SHH signaling, 
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Table 4-1.  
 
Drug treatment Proposed action Effect on afferent 
extension 
BDNF Survival, trophic and 
growth factor 
Enhance 
Fingolimod-p S1PR agonist, promotes 





R agonist Enhance 
αBDNF Blocks BDNF Attenuates 
W123 S1P
1
R antagonist Attenuates 
Fingolimod-p + SEW2871 Agonists of S1P
1
R Enhances  





K252a Inhibits all Trk receptors  Attenuates 
TrkB IgG function 
blocking antibody 
Inhibits TrkB Attenuates  
U73122 Blocks PLC-γ signaling  Attenuates 
LY294002 Blocks PI3K signaling  Attenuates 
U0126 Blocks MAPK signaling  No effect 
PD98059 Blocks MAPK signaling  No effect 
Xe-C Blocks IP
3





OAG DAG analogue No effect 
Bim1 PKC inhibitor No effect 
BDNF + U0126 Stimulates TrkB and blocks 




BDNF + LY294002 Stimulates TrkB and blocks 




BDNF + U73122  Stimulates TrkB and blocks 






































Table 4-1. Summary of results. Primary sensory afferent extension can be manipulated 
pharmacologically. Afferents extension is enhanced or attenuated when exposed to the 
above described pharmacological agents relative to vehicle control treatment (artificial 
cerebral spinal fluid + 1% DMSO). Both pharmacological treatment and vehicle control 
treatment were for five hours and under identical culture conditions.  
 
*Denotes afferent extension was enhanced, attenuated or not affected relative to BDNF 































Drug Proposed action Effect on afferent 




Blebbistatin Blocks myosin II Attenuates Robinson et al., 
(2015)a 





Attenuates Robinson et al., 
(2015)a 
Nocodzaole Interferes with 
microtubule 
polymerization 
Attenuates Mariani et al., 
(2015)a 
Latrunculin Actin stabilizer Enhances Mariani et al., 
(2015)a 
Jasplakinolide Promotes actin 
polymerization 
Enhances Mariani et al., 
(2015)a 
H89 Blocks cAMP 
substrate PKA 






















Table 4-2. DRG afferent extension in longitudinal pathway of embryonic chicken. 
Summary of results from other investigations of afferent extension in embryonic chicken 
E5 HH st. 25 with an in situ preparation unless otherwise noted. Afferents extension is 
enhanced or attenuated when exposed to the above described pharmacological agents 
relative to vehicle control treatment (artificial cerebral spinal fluid + 1% DMSO). Both 
pharmacological treatment and vehicle control treatment were for five hours and under 
identical culture conditions.  
a Unpublished findings.  


































Figure 4-1. Model for regulation of afferent extension in the longitudinal pathway of 
E5 HH st.25 chicken DRG neuron at the growth cone.  The following events are 
thought to occur in the growth cone of the DRG afferent unless otherwise stated. BDNF 
binds to and activates TrkB. Activation of TrkB then promotes release of IP3 sensitive 
Ca2+ stores via activation of the PLC-γ signaling pathway. Elevation of intracellular Ca2+ 
activates CaMKII phosphorylation of CaMKI and subsequent phosphorylation and 
activation of RhoGTPases, proteins known to interact with the actin cytoskeleton and 
promote growth cone motility via actin polymerization and de-polymerization. 
Additionally, CaMKI phosphorylates Myosin II, a mechanoenzyme important for neuron 
substrate adhesion and afferent axon extension within the longitudinal pathway. 
Additionally, exposure to fingolimod-p enhances BDNF mRNA transcription via 
activation of S1P1R, subsequent elicitation of MAPK signaling and phosphorylation of 
CREB. P-CREB binds to DNA and promotes transcription of BDNF mRNA which then 
becomes translated to protein and released from the axon growth cone.  BDNF then acts 
in an autocrine manner on TrkB receptors through the above described mechanism.  
 
*Occurs in the cell body. 
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